Clinical Insights: November 21st, 2025
Welcome to Pillr Health’s Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace.
New Drug/Vaccine Approval
Komzifti™ (ziftomenib) Capsules - New Drug Approval – November 13, 2025 – The Food and Drug Administration approved ziftomenib (Komzifti™, Kura Oncology, Inc.), a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation who have no satisfactory alternative treatment options. <Read More>
Kygevvi® (doxecitine and doxribtimine) Powder for Oral Solution - New Drug Approval –November 3, 2025 – The U.S. Food and Drug Administration (FDA) approved Kygevvi® (doxecitine and doxribtimine) powder to treat thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients who start to show symptoms when they are 12 years old or younger. Kygevvi® received Breakthrough Therapy Designation for this indication. <Read More>
Lynkuet® (elinzanetant) Capsules - New Drug Approval – October 24, 2025 – Bayer announced the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy, neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause. <Read More>
Javadin™ (clonidine hydrochloride) Oral Solution - New Drug Approval – October 23, 2025 – Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Javadin™ (clonidine hydrochloride) oral solution, the only FDA-approved, immediate-release, ready-to-use oral liquid clonidine formulation for the treatment of hypertension in adult patients to lower blood pressure. <Read More>
Epioxa™ (riboflavin 5’-phosphate) Ophthalmic Solution - New Drug Approval – October 17, 2025 - Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced the U.S. Food and Drug Administration (FDA) approved its Epioxa™ HD / Epioxa™ (“Epioxa”) New Drug Application (NDA). Epioxa™ is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated. <Read More>
Ferabright™ (ferumoxytol) Injection - New Drug Approval – October 16, 2025 - Azurity Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Ferabright™ (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier. <Read More>
New Label Expansions
Elevidys® (delandistrogene moxeparvovec-rokl) Suspension for Intravenous Infusion – New Label Expansion – November 14, 2025 - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced an update to the prescribing information for Elevidys® (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy (DMD). <Read More>
Darzalex Faspro® (daratumumab and hyaluronidase-fihj) Injection – New Label Expansion – November 6, 2025 - Johnson & Johnson (NYSE:JNJ) announced the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM). Darzalex Faspro® is the first and only approved treatment for HR-SMM, enabling earlier intervention before the disease progresses to active multiple myeloma. <Read More>
Caplyta® (lumateperone) Capsules – New Label Expansion – November 5, 2025 - Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) approved Caplyta® (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. <Read More>
Linzess® (linaclotide) Capsules – New Label Expansion – November 4, 2025 - The U.S. Food and Drug Administration (FDA) has approved Linzess® (linaclotide) capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation (IBS-C). Linzess® is the first treatment approved for IBS-C in pediatric patients. <Read More>
Stoboclo® (denosumab-bmwo) Injection – New Label Expansion – October 29, 2025 – Celltrion, Inc. announced that the U.S. Food and Drug Administration (FDA) has designated Stoboclo® (denosumab-bmwo) and Osenvelt® (denosumab-bmwo) as interchangeable biosimilars to the reference products Prolia® (denosumab) and Xgeva® (denosumab), respectively, for all approved indications. <Read More>
Conexxence® (denosumab-bnht) Injection – New Label Expansion – October 29, 2025 - Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced that the U.S. Food and Drug Administration (FDA) designated Conexxence® and Bomyntra® (denosumab-bnht) as interchangeable biosimilars to the reference products, Prolia® (denosumab) and Xgeva® (denosumab), respectively. <Read More>
Winrevair™ (sotatercept) for Injection – New Label Expansion – October 24, 2025 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH trial for Winrevair™ (sotatercept-csrk) for injection, 45mg, 60mg. Winrevair™, an activin signaling inhibitor, is now FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death. <Read More>
Revuforj® (revumenib) Tablets – New Label Expansion – October 24, 2025 - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options. <Read More>
Blenrep® (belantamab mafodotin-blmf) Injection – New Label Expansion – October 23, 2025 - GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Blenrep® (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory (IMID) agent. <Read More>
Omvoh® (mirikizumab-mrkz) Injection – New Label Expansion – October 23, 2025 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh® (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC). <Read More>
Gazyva® (obinutuzumab) Injection – New Label Expansion – October 17, 2025 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has approved Gazyva® (obinutuzumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for eligible patients. <Read More>
New Drug Shortage
November 17, 2025
Montelukast Sodium Tablet, Chewable (Discontinuation)
November 14, 2025
Ceftazidime Injection (Discontinuation)
Palonosetron Hydrochloride Injection (Discontinuation)
Somatropin Injection (Discontinuation)
Vancomycin Hydrochloride Injection (Discontinuation)
November 13, 2025
Adalimumab-ryvk Kit (Discontinuation)
Cetrorelix Acetate Injection (Discontinuation)
Guanfacine Hydrochloride Tablet, Extended Release (Discontinuation)
November 12, 2025
Frovatriptan Succinate Tablet (Discontinuation)
November 7, 2025
Atropine Sulfate Injection (Discontinuation)
Calcium Chloride Injection (Discontinuation)
Deferiprone Tablet (Discontinuation)
Dextrose Monohydrate 50% Injection (Discontinuation)
Epinephrine Injection (Discontinuation)
Ketamine Hydrochloride Injection (Discontinuation)
Lidocaine Hydrochloride Injection (Discontinuation)
Sodium Bicarbonate Injection (Discontinuation)
Updated Drug Shortage
November 18, 2025
Metronidazole Injection (Discontinuation)
November 17, 2025
Flurazepam Hydrochloride Capsule (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
November 14, 2025
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Meperidine Hydrochloride Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
Sterile Water Injection (Currently in Shortage)
Sufentanil Citrate Injection (Currently in Shortage)
November 13, 2025
Azacitidine Injection (Currently in Shortage)
Bumetanide Injection (Currently in Shortage)
Cefotaxime Sodium Powder, for Solution (Currently in Shortage)
Dexamethasone Sodium Phosphate Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Liraglutide Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Promethazine Hydrochloride Injection (Currently in Shortage)
Propranolol Hydrochloride Injection (Currently in Shortage)
Remifentanil Hydrochloride Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
Sterile Water Injection (Currently in Shortage)
Sufentanil Citrate Injection (Currently in Shortage)
Valproate Sodium Injection (Currently in Shortage)
November 10, 2025
Amino Acid Injection (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Dexmedetomidine Hydrochloride Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Nitroglycerin Injection (Currently in Shortage)
Sterile Water Irrigant (Currently in Shortage)
New Drug Recall and Safety Alerts
Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL Vial by Fresenius Kabi – New Voluntary Recall – November 7, 2025 - Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies is voluntarily recalling three lots (numbers 6133156, 6133194, 6133388) of Famotidine Injection, USP, 20 mg per 2 mL (10 mg per mL), 2 mL Fill in a 2 mL vial. This recall is being performed to the user level in the United States. <Read More>
Potassium Chloride 20 mEq Injection by Otsuka ICU Medical LLC – New Voluntary Recall – November 3, 2025 – Otsuka ICU Medical LLC is issuing a voluntary recall to the user level, for a MISLABELLED lot of POTASSIUM CHLORIDE Inj. 20 mEq, NDC 0990-7077-14. The OVERWRAP label of lot 1030613, Expiration Date: 09-30-2026 may incorrectly identify the product as POTASSIUM CHLORIDE Inj. 10 mEq with NDC 0990-7074-26. <Read More>
New Generic/Biosimilar Approval and Launch
Poherdy™ (pertuzumab-dpzb) Injection - New Perjeta® Biosimilar Approval – November 13, 2025 – The Food and Drug Administration approved Poherdy™ (pertuzumab-dpzb, Shanghai Henlius Biologics Co. Ltd.) as an interchangeable biosimilar to Perjeta® (pertuzumab, Genentech Inc.). This is the first approval of a biosimilar for Perjeta®. <Read More>
Clinical and Pharmacy News
Government Shutdown Now Over as Federal Agencies Reopen and Employees Return to Work – November 13, 2025 – With the shutdown finally in the rearview mirror, the focus in the Senate is turning to an upcoming fight over health care, with Democrats hoping to regroup after splintering in the final stages of the showdown. Eight Senate Democrats broke ranks to reach a deal with Republicans to end the shutdown, dashing the party's effort to win an extension of expiring Affordable Care Act tax credits in return for their vote to reopen the government. Now, Democrats face a quick timeline to shift their strategy. <Read More>
ADHD Medication Recalled Nationwide Because Users Aren’t Getting the Full Effect – November 11, 2025 – A popular ADHD medication is being recalled nationwide because its users won’t be able to get the full effect. According to the Food and Drug Administration, several lots of lisdexamfetamine dimesylate capsules, a generic form of Vyvanse®, are being recalled. The recall was announced Oct. 28. The Board of Pharmacy said the medication failed dissolution tests, writing, “Dissolution is important for drugs to be absorbed and have a physiological effect on the human body; they must be in solution. The impacted capsules would not be able to deliver an optimal level of medicine and may impact the therapeutic efficacy of the product.” <Read More>
CMS Announces GENEROUS Model to Lower Medicaid Drug Prices – November 6, 2025 – CMS announced the GENErating cost Reductions fOr U.S. Medicaid (GENEROUS) Model, a new drug payment model that will aim to lower prescription drug spending in Medicaid and strengthen the program overall. The GENEROUS model, launching in 2026, will allow participating states to purchase drugs included in the pilot at prices in line with those in other nations, with a goal of increasing access to medications and improving health outcomes among Medicaid beneficiaries. The announcement adds to a recent flurry of Trump administration initiatives aimed at addressing high drug prices in the US, including the Most Favored Nation (MFN) executive order and subsequent drug pricing deals with Pfizer, AstraZeneca, Novo Nordisk, and Eli Lilly and Company. <Read More>
Certain Obesity Drugs Will Cost as Little as $149 And Medicare Will Start Covering Them Under White House Deals – November 6, 2025 – Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.The arrangements with drugmakers Eli Lilly and Novo Nordisk, which President Donald Trump foreshadowed in remarks last month, are the latest in the administration’s efforts to lower drug prices. As part of the new deals, the drugmakers have also agreed to match prices to the lowest paid in peer nations for all their drugs in Medicaid as well as for the list prices when their medications first hit the market. They will also offer primary care medicines directly to consumers at discounted prices. <Read More>
New Data Shows Local Pharmacy Shortages – November 5, 2025 – A new mapping tool from the National Community Pharmacists Association and University of Southern California shows a few pharmacy shortage areas in the Tri-Cities. At least three suburban and five rural neighborhoods are considered lacking across Carter, Hawkins, Johnson, Sullivan, Unicoi and Washington counties. Southwest Virginia also has three shortage areas between Bristol and Abingdon. These regions are defined by how far people need to travel to reach the nearest pharmacy: more than 10 miles in rural areas, two miles in suburbs and one mile in urban neighborhoods. Community pharmacies are critical access points in their communities, said Dr. Ronna Hauser, senior vice president of policy and pharmacy affairs for the NCPA. <Read More>
Evaluating Pediatric Medication Errors: A Feasibility Study – November 5, 2025 - In a groundbreaking study published in BMC Pediatrics, researchers have delved into a critical yet often overlooked aspect of pediatric healthcare: medication discrepancies. The research conducted by an experienced team, including Mercümek, Bektay, and Uzuner, among others, sheds light on the alarming inconsistencies that can occur in the medication administered to young patients. The objective of this study was to evaluate the occurrence of medication discrepancies within a pediatric ward, utilizing a novel framework known as the Medication Discrepancy Taxonomy (MedTax). <Read More>
AFPs Affect Access to Specialty Medications – October 30, 2025 - The use of alternative funding programs (AFPs) significantly reduces the likelihood of beneficiaries accessing needed medications, increases time to treatment, and is associated with more gaps in therapy and adverse clinical outcomes compared with traditional pharmacy benefits. Pharmacists at a dozen health systems presented these new results about AFPs—for-profit third-party vendors used by self-funded employer plans that carve out certain medications as “nonessential health benefits” and attempt to obtain medication from non-health plan sources—in a presentation at AMCP Nexus 2025, in National Harbor, Maryland (poster 138). <Read More>
Many Unanswered Questions: Will the Trump Administration’s Drug Pricing Deals Result in Any Cost Savings for State Medicaid Programs? – October 29, 2025 - Over the last month, the White House has widely touted pricing agreements from two drug manufacturers — Pfizer and AstraZeneca — which it claims will result in substantial prescription drug cost savings for state Medicaid programs. According to the White House, under these agreements, the manufacturers will provide “Most Favored Nation (MFN)” prices, based on lower international prices paid by other nations, to all state Medicaid programs. This follows from a May 2025 executive order promoting MFN pricing. <Read More>
EmblemHealth taps Prime Therapeutics, Amazon for new Pharmacy Benefit Collaboration – October 29, 2025 - New York-based insurer EmblemHealth is teaming up with Prime Therapeutics to rethink the pharmacy benefit experience for its members. Emblem will tap into Prime's tech stack, which allows real-time referrals for specialty drugs instead of the more traditional network structure. In this model, it encourages competitive pricing for specialty products when ensuring members feel the savings directly, the insurer said in an announcement. <Read More>
340B in the News
Rage Over Rebates: Hospitals Oppose 340B Pilot Program – November 12, 2025 - The federal government is testing a new method of delivering discounts in a program aimed to help hospitals buy certain drugs at lower prices, and health systems aren’t happy about it. The government is testing a new pilot program that would move from hospitals simply buying the drugs at lower prices in the federal 340B Drug Discount Program. The Health Resources and Services Administration said late last month it’s testing a new program with eight companies that would offer rebates to hospitals after they have purchased the drugs. The agency said it is testing plans from large drug companies including Bristol Myers Squibb, Astra Zeneca, and Novo Nordisk Inc. The pilot program is slated to launch Jan. 1. <Read More>
340B Rebate Models and Medicare Part D 340B Claims: What 340B Covered Entities Need to Know for 2026 – November 11, 2025 – 340B covered entities should carefully review the approved 340B rebate models and the 2026 Medicare Physician Fee Schedule (MPFS) Final Rule provisions on new CMS processes for identifying Medicare Part D claims for 340B drugs. While the current scope may seem limited or not applicable to certain 340B covered entities, now is the most important time to evaluate the implications of these programs if expanded to all 340B drugs and all 340B covered entities in order to ensure that the concerns of 340B covered entities are appropriately addressed. <Read More>
Clinical Insights: November 19, 2026
New Drug/Vaccine Approval
Pimjetmi® (pimicotinib) Capsules – New Drug Approval – November 10, 2026 – The Food and Drug Administration approved pimicotinib (Pimjetmi®, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. <Read More>
Sunharbo® (asundexian) Tablets – New Drug Approval – November 9, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). <Read More>
Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Injection – New Drug Approval – October 30, 2026 – The U.S. Food and Drug Administration granted accelerated approval for Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) that leads to the formation of small, wart-like growths in the patient’s airways. <Read More>
Hibsago® (bepirovirsen) Injection – New Drug Approval – October 20, 2026 – The U.S. Food and Drug Administration approved Hibsago® (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago® is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. <Read More>
Brytly™ (apraclonidine hydrochloride) Ophthalmic Solution – New Drug Approval – October 16, 2026 – The U.S. Food and Drug Administration approved a new nonprescription eye drop treatment, Brytly™, apraclonidine ophthalmic solution, 0.125%, for relief of eye redness due to minor irritations. This is the first nonprescription eye drop with apraclonidine. <Read More>
Hovilpri® (pritelivir) Tablets – New Drug Approval – October 9, 2026 – FDA has approved Hovilpri® (pritelivir) tablets for adults with weakened immune systems (i.e., immunocompromised patients) who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Mucocutaneous lesions occur on skin or mucosal surfaces, such as lips, nostrils, eyes and genitals. <Read More>
Weltruza™ (olanzapine) Powder for Extended-Release Injectable Suspension – New Drug Approval – October 8, 2026 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved Weltruza™ (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. Weltruza™ clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP). <Read More>
Emcitate® (tiratricol) Tablets for Oral Suspension – New Drug Approval – September 28, 2026 – The U.S. Food and Drug Administration approved Emcitate® (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. <Read More>
Juvmo™ (tavapadon) Tablets – New Drug Approval – September 25, 2026 - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved Juvmo™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive neurological disorder that affects millions of people worldwide. <Read More>
New Label Expansions
Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) Injection – New Expanded Label – November 5, 2026 - Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody. <Read More>
Ilumya® (tildrakizumab-asmn) Injection – New Expanded Label – October 30, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associated companies) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Ilumya® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). <Read More>
Talzenna® (talazoparib) Capsules – New Expanded Label – October 26, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna® (talazoparib) in combination with Xtandi® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. <Read More>
Skyrizi® (risankizumab-rzaa) Injection – New Expanded Label – October 23, 2026 - AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi® (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD). Patients now have the option to start Skyrizi® treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment. <Read More>
Awiqli® (insulin icodec-abae) Injection – New Expanded Label – October 23, 2026 - Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first once-weekly, long-acting basal insulin, as an adjunct to diet and exercise to improve glycemic control (blood sugar) in children 10 years of age and older with type 2 diabetes. This approval offers a once-weekly basal insulin treatment option, which reduces the frequency of weekly basal injections from seven to one per week. <Read More>
Ultomiris® (ravulizumab-cwvz) Injection – New Expanded Label – October 21, 2026 - Alexion, AstraZeneca Rare Disease’s Ultomiris® (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether Ultomiris® slows kidney function decline in patients with IgAN. <Read More>
Jemperli® (dostarlimab-gxly) Injection – New Expanded Label – October 19, 2026 - GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Jemperli® (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway. <Read More>
Orladeyo® (berotralstat) Capsules and Oral Pellets – New Expanded Label – October 16, 2026 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for use of the oral pellet formulation of once-daily Orladeyo® (berotralstat) for prophylactic therapy in adults and adolescents aged 12 years and older. The new 150 mg Orladeyo® pellet formulation provides an alternative administration option for adults and adolescents who may have difficulty swallowing, prefer not to take a capsule or choose to remain on a pellet formulation beyond age 12. <Read More>
Ryzumvi® (phentolamine mesylate) Ophthalmic Solution – New Expanded Label – October 16, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. Ryzumvi® is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. <Read More>
Enspryng® (satralizumab-mwge) Injection – New Expanded Label – October 15, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. <Read More>
Zilbrysq® (zilucoplan) Injection – New Expanded Label – October 15, 2026 - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with Zilbrysq® (zilucoplan). The autoinjector is designed to help simplify self-administration of Zilbrysq®, offering patients another administration option and a more convenient treatment experience. <Read More>
Evoxac® (cevimeline hydrochloride) Capsules and Oral Solution – New Expanded Label – October 15, 2026 - Cosette Pharmaceuticals, Inc. (“Cosette”), a U.S.-based specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Evoxac® (cevimeline HCl) oral solution for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. <Read More>
Anktiva® (nogapendekin alfa inbakicept-pmln) – New Expanded Label – October 14, 2026 - The U.S. Food and Drug Administration expanded the approved use of Anktiva® (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment. Anktiva® is the first FDA-approved treatment specifically for patients with BCG-unresponsive, high-grade papillary-only disease. <Read More>
Tecentriq® (atezolizumab) Injection – New Expanded Label – October 8, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. <Read More>
Tukysa® (tucatinib) Tablets – New Expanded Label – October 7, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Tukysa® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. <Read More>
Rhapsido® (remibrutinib) Tablets – New Expanded Label – October 6, 2026 - Novartis announced that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. The approval represents an important advancement for people whose chronic hives and itch can be triggered by everyday skin friction, scratching, or rubbing. <Read More>
Jaypirca® (pirtobrutinib) Tablets – New Expanded Label – October 2, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts the December 2023 accelerated approval for later-line CLL/SLL to a traditional approval. <Read More>
Camzyos® (mavacamten) Capsules – New Expanded Label – September 30, 2026 - Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved Camzyos® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. Camzyos® now has the broadest indication of any cardiac myosin inhibitor (CMI). <Read More>
Gazyva® (obinutuzumab) – New Expanded Label – September 25, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has received U.S. Food and Drug Administration (FDA) approval of Gazyva® (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. <Read More>
Olumiant® (baricitinib) Tablets – New Expanded Label – September 25, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Olumiant® (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA). The approval expands Olumiant®’s U.S. label, building on its established use in adults with moderately to severely active rheumatoid arthritis and severe AA. AA is a chronic immune-mediated disease that causes unpredictable hair loss. <Read More>
Yusimry® (adalimumab-aqvh) Injection – New Expanded Label – September 25, 2026 - Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced that the U.S. Food and Drug Administration (“FDA”) has approved a high-concentration formulation (“HCF”) for Yusimry® (adalimumab-aqvh), as an interchangeable biosimilar to Humira. <Read More>
New Drug Shortage
November 16, 2026
Abacavir Sulfate Injection (Discontinuation)
Lamivudine Injection (Discontinuation)
Olipudase alfa-rpcp Injection (Currently in Shortage)
November 13, 2026
Bendamustine Hydrochloride Injection (Discontinuation)
Propranolol Hydrochloride Capsule, Extended Release (Discontinuation)
Somatropin Injection (Discontinuation)
Valrubicin Solution (Discontinuation)
November 6, 2026
Lincomycin Hydrochloride Injection (Discontinuation)
November 5, 2026
Tadalafil Tablet (Discontinuation)
October 30, 2026
Cefazolin in Dextrose Injection (Discontinuation)
Cefepime Hydrochloride Injection (Discontinuation)
Ceftriaxone Sodium Injection (Discontinuation)
Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension/Drops (Discontinuation)
Updated Drug Shortage
November 13, 2026
Hydroxocobalamin Injection (Currently in Shortage)
November 10, 2026
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
November 9, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Etomidate Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Pentostatin Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
Sufentanil Citrate Injection (Currently in Shortage)
November 6, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Dexmedetomidine Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
November 4, 2026
Clonazepam Tablet (Resolved)
New Drug Recall and Safety Alerts
Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter – November 9, 2026 - Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the presence of particulate matter identified as a glass particle inside the vial. <Read More>
Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter – October 14, 2026 - Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel, that was detected in certain lots. <Read More>
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter – October 9, 2026 - Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose. <Read More>
Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels – October 1, 2026 – Greenwich RxExternal Link Disclaimer, a 503A compounding pharmacy, is voluntarily recalling specific lots of its compounded glutathione to the consumer level. The product is being recalled due to potential elevated endotoxin levels. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection – September 21, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
New Generic/Biosimilar Approval and Launch
Lucamzi™ (ranibizumab-blrz) Injection – New Lucentis® Biosimilar Approval – October 27, 2026 – Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2027 together with its partners. <Read More>
Clinical and Pharmacy News
URGENT Notice to NCPDP Pharmacy Provider Members Using IINs (BINs) Recommendations to Address Risks with the Transition from the Six-Digit IIN (BIN) to Eight-Digit IIN (BIN) – This is a notification from the NCPDP Strategic National Implementation Process (SNIP) Committee to assist pharmacy provider stakeholders with the transition from the six-digit IIN (formerly known as BIN) to the eight-digit IIN. The compliance dates associated with several CMS final rules recently published set a more distinct timeline as to when various systems and processes should begin using the eight-digit IIN. Stakeholders are encouraged to review the information and recommendations below. Also reference other NCPDP resources to coordinate implementation timelines and mitigate transaction processing barriers. <Read More>
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin – November 16, 2026 – Modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin officially took effect November 15, 2026, introducing changes intended to reduce administrative burdens for patients, prescribers, and pharmacies while maintaining safeguards against fetal exposure to the medication. <Read More>
WHO Issues First Guidelines on Type 1 Diabetes for Adults – November 14, 2026 – More than 100 years after the discovery of insulin, many people living with type 1 diabetes still cannot access the insulin and care they need to survive. Type 1 diabetes is a lifelong condition in which the body does not produce enough insulin, making people dependent on daily insulin to survive. Marking World Diabetes Day 2026, the World Health Organization (WHO) has issued its first guidelines on the diagnosis and management of type 1 diabetes in adults, with recommendations designed to apply across all settings, including low-resource, emergency and humanitarian settings. <Read More>
AHA 2026: Pharmacists at the Center of Cardiometabolic Care – November 13, 2026 - When the American Heart Association (AHA) Scientific Sessions 2026 convened in Chicago, Illinois, from November 6 to 9, 2026, the data spanned a new class of incretin-based therapy, longer-term results for the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, blood pressure effects of an oral glucagon-like peptide-1 (GLP-1) receptor agonist, and real-world models of heart failure (HF) care. Across Pharmacy Times interviews and abstract coverage from the meeting, a common theme emerged: pharmacists are increasingly central to how new cardiometabolic therapies are titrated, monitored, and sustained. <Read More>
DOL Finalizes Pharmacy Benefit Manager Fee Disclosure Rule: What PBMs Must Disclose, and Should be Ready to Defend – November 4, 2026 – Pharmacy benefit managers (PBMs) that serve large, self-insured health plans will have to give employers a detailed account of how they are paid under a rule the U.S. Department of Labor (DOL) finalized on October 29, 2026. Employers will also have the right to audit that information. PBMs have time to prepare but should not wait. A PBM that wants to rely on the 90-day advance-notice benchmark for renewals will need its disclosures ready well before the rule applies. <Read More>
How the Biosimilars Access and Affordability Act Redefines IRA Delays – November 3, 2026 - Congress is again weighing changes to how the Inflation Reduction Act (IRA) treats biologics facing imminent biosimilar competition. The Biosimilars Access and Affordability Act (H.R. 10628/S. 5571), reintroduced in both the House and Senate, would create clearer criteria for delaying Medicare price negotiation of a reference biologic when a biosimilar is expected to reach the market while keeping the IRA’s 2-year maximum delay. Under the bill, manufacturers would certify their expected launch information, and if the biosimilar is not licensed and marketed within the 2-year period, the reference biologic would enter negotiation, and its manufacturer would owe rebates covering the delayed years. <Read More>
340B in the News
Protecting the 340B Program Means Protecting Patients First – November 13, 2026 – Every month roughly 30 patients at Third Street Health Center in Ohio pick up their prescriptions for about $6. Beginning in January, some of those same prescriptions could cost them more than $500. That is what a new federal rebate pilot program means for community health centers, the providers that use the 340B Drug Pricing Program exactly as Congress intended. Plenty has been written about the abuse of 340B, but CHCs are model stewards of the program and are required to reinvest any savings back into patient care. <Read More>
340B Cuts Softened, Site-Neutral Expansion Progresses in CMS CY 2027 OPPS Final Rule – November 5, 2026 - CMS finalized 340B drug reimbursement at ASP minus 28%, less than the proposed 33.4% cut, while accelerating the annual recoupment offset to 2% through 2031. The agency will reimburse imaging without contrast at grandfathered off-campus hospital outpatient departments at the Physician Fee Schedule equivalent, setting the rate at 40% of the standard OPPS rate. Hospitals will receive a net 2.3% payment update that industry advocates criticize as insufficient, alongside the removal of 637 services from the Inpatient Only list. <Read More>
Medicare Will Cut Billions From 340B, Expand Site-Neutral Payments in 2027 – November 5, 2026 - Medicare will slash payment rates for a federal drug discount program and broaden site-neutral policies next year, according to a final rule released by the CMS on Wednesday. 340B payments are set to drop by billions of dollars and Medicare will pay the same amount for more medical procedures, regardless if they’re furnished in hospital-owned outpatient departments. Under the final rule, hospital outpatient departments and ASCs will also see their Medicare payments increase 2.3% next year, slightly less than the 2.4% bump regulators proposed in July. <Read More>
Pharmacy Benefit Managers Take Savings Intended for 340B Providers Serving Vulnerable Patients – November 4, 2026 – A “pharmacy benefit manager” is a kind of middleman company that administers prescription drug benefits for insurers and employers, managing formularies, negotiating manufacturer rebates, processing claims, and overseeing pharmacy networks…But here’s how PBMs can legally steal every day from 340B safety-net nonprofit providers that Congress intended to invest back in services for vulnerable populations. Through corporate vertical integration, PBMs such as CVS Health, Express Scripts, and OptumRx own or control pharmacies participating in 340B, allowing them to capture portions of the drug-discount margin. Five major PBMs control 75% of 340B contract-pharmacy relationships, while more than half of contract-pharmacy 340B savings are going to CVS, which owns Aetna; Cigna, which owns Express Scripts; and United Healthcare, which owns Optum Rx. <Read More>
CMS Finalizes Increases to Medicare Hospital Outpatient Department Payment Rates, Changes to Site-Neutral and 340B for 2027 – November 4, 2026 – The Centers for Medicare & Medicaid Services Nov. 4 issued a final rule that increases Medicare hospital outpatient prospective payment system rates by a net 2.3% in calendar year 2027 compared to 2026. This includes a 3.2% market basket update, offset by a 0.9 percentage point cut for productivity. In a statement shared with the media, Ashley Thompson, AHA senior vice president of public policy analysis and development, said, “CMS’ Medicare outpatient hospital payment rate does not adequately take into account the financial challenges facing hospitals today. These challenges are amplified for hospitals serving rural and underserved communities, many of which are already making hard decisions about how they will maintain access to healthcare services in their communities.” <Read More>
Understanding the Origins of the 340B Drug Pricing Program – October 29, 2026 – Although nearly half of all U.S. hospitals participate in it, few Americans have heard of the 340B Drug Pricing Program. The program was designed to allow health care providers that serve low-income and uninsured patients, such as federally qualified health centers (FQHCs), to buy drugs from manufacturers at significant discounts to offset losses from uncompensated care. However, the program has grown significantly over time to include more than 60,000 clinical sites and accounts for more than $100 billion in discounted spending. Because discounted drugs can be used for all patients — not just those who cannot pay — providers participating in the program can generate revenue from billing discounted drugs to payers, including Medicaid, Medicare, and private insurance. Critics of the program have raised questions regarding hospitals’ use of revenue from the program. <Read More>
Manufacturer Notices to 340B Covered Entities
Clinical Insights: November 19, 2026
New Drug/Vaccine Approval
Pimjetmi® (pimicotinib) Capsules – New Drug Approval – November 10, 2026 – The Food and Drug Administration approved pimicotinib (Pimjetmi®, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. <Read More>
Sunharbo® (asundexian) Tablets – New Drug Approval – November 9, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Sunharbo® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic ischemic stroke (NIHSS ≤15) or high-risk transient ischemic attack (TIA). <Read More>
Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Injection – New Drug Approval – October 30, 2026 – The U.S. Food and Drug Administration granted accelerated approval for Voceryq™ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) that leads to the formation of small, wart-like growths in the patient’s airways. <Read More>
Hibsago® (bepirovirsen) Injection – New Drug Approval – October 20, 2026 – The U.S. Food and Drug Administration approved Hibsago® (bepirovirsen) injection, in combination with existing antiviral therapy, to treat chronic hepatitis B virus (HBV) infection in certain adults without cirrhosis. Hibsago® is the first FDA-approved antisense oligonucleotide to treat chronic hepatitis B. <Read More>
Brytly™ (apraclonidine hydrochloride) Ophthalmic Solution – New Drug Approval – October 16, 2026 – The U.S. Food and Drug Administration approved a new nonprescription eye drop treatment, Brytly™, apraclonidine ophthalmic solution, 0.125%, for relief of eye redness due to minor irritations. This is the first nonprescription eye drop with apraclonidine. <Read More>
Hovilpri® (pritelivir) Tablets – New Drug Approval – October 9, 2026 – FDA has approved Hovilpri® (pritelivir) tablets for adults with weakened immune systems (i.e., immunocompromised patients) who have mucocutaneous lesions caused by herpes simplex virus (HSV) infection and have not responded to other therapies (acyclovir, valacyclovir, or famciclovir). Mucocutaneous lesions occur on skin or mucosal surfaces, such as lips, nostrils, eyes and genitals. <Read More>
Weltruza™ (olanzapine) Powder for Extended-Release Injectable Suspension – New Drug Approval – October 8, 2026 – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved Weltruza™ (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. Weltruza™ clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP). <Read More>
Emcitate® (tiratricol) Tablets for Oral Suspension – New Drug Approval – September 28, 2026 – The U.S. Food and Drug Administration approved Emcitate® (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. <Read More>
Juvmo™ (tavapadon) Tablets – New Drug Approval – September 25, 2026 - AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved Juvmo™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson’s disease, a progressive neurological disorder that affects millions of people worldwide. <Read More>
New Label Expansions
Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) Injection – New Expanded Label – November 5, 2026 - Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Rybrevant Faspro™ (amivantamab and hyaluronidase-lpuj) (subcutaneous injection, 160 mg/2,000 units per mL) as a single agent for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum‑based chemotherapy and an anti‑PD‑(L)1 antibody. <Read More>
Ilumya® (tildrakizumab-asmn) Injection – New Expanded Label – October 30, 2026 - Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associated companies) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Ilumya® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA). <Read More>
Talzenna® (talazoparib) Capsules – New Expanded Label – October 26, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has expanded approval of Talzenna® (talazoparib) in combination with Xtandi® (enzalutamide) to the treatment of men with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (PC) with homologous recombination repair (HRR) gene mutations, including both BRCA and non-BRCA mutations. <Read More>
Skyrizi® (risankizumab-rzaa) Injection – New Expanded Label – October 23, 2026 - AbbVie (NYSE: ABBV) announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi® (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD). Patients now have the option to start Skyrizi® treatment at home, with induction doses delivered by an on-body injector (OBI) induction pack and then continue using an OBI once every eight weeks throughout the course of maintenance treatment. <Read More>
Awiqli® (insulin icodec-abae) Injection – New Expanded Label – October 23, 2026 - Novo Nordisk announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first once-weekly, long-acting basal insulin, as an adjunct to diet and exercise to improve glycemic control (blood sugar) in children 10 years of age and older with type 2 diabetes. This approval offers a once-weekly basal insulin treatment option, which reduces the frequency of weekly basal injections from seven to one per week. <Read More>
Ultomiris® (ravulizumab-cwvz) Injection – New Expanded Label – October 21, 2026 - Alexion, AstraZeneca Rare Disease’s Ultomiris® (ravulizumab) has been approved in the US to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether Ultomiris® slows kidney function decline in patients with IgAN. <Read More>
Jemperli® (dostarlimab-gxly) Injection – New Expanded Label – October 19, 2026 - GSK plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved Jemperli® (dostarlimab-gxly) as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer under the accelerated approval pathway. <Read More>
Orladeyo® (berotralstat) Capsules and Oral Pellets – New Expanded Label – October 16, 2026 - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for use of the oral pellet formulation of once-daily Orladeyo® (berotralstat) for prophylactic therapy in adults and adolescents aged 12 years and older. The new 150 mg Orladeyo® pellet formulation provides an alternative administration option for adults and adolescents who may have difficulty swallowing, prefer not to take a capsule or choose to remain on a pellet formulation beyond age 12. <Read More>
Ryzumvi® (phentolamine mesylate) Ophthalmic Solution – New Expanded Label – October 16, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Ryzumvi® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults. Ryzumvi® is currently approved in the United States for the treatment of pharmacologically-induced mydriasis and is the only commercially available FDA-approved product for that use. <Read More>
Enspryng® (satralizumab-mwge) Injection – New Expanded Label – October 15, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved Enspryng® (satralizumab-mwge) for the treatment of adults with thyroid eye disease (TED), providing patients with the first and only at-home subcutaneous treatment option. <Read More>
Zilbrysq® (zilucoplan) Injection – New Expanded Label – October 15, 2026 - UCB (Euronext Brussels: UCB), a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with Zilbrysq® (zilucoplan). The autoinjector is designed to help simplify self-administration of Zilbrysq®, offering patients another administration option and a more convenient treatment experience. <Read More>
Evoxac® (cevimeline hydrochloride) Capsules and Oral Solution – New Expanded Label – October 15, 2026 - Cosette Pharmaceuticals, Inc. (“Cosette”), a U.S.-based specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved Evoxac® (cevimeline HCl) oral solution for the treatment of symptoms of dry mouth in adults with Sjögren’s disease. <Read More>
Anktiva® (nogapendekin alfa inbakicept-pmln) – New Expanded Label – October 14, 2026 - The U.S. Food and Drug Administration expanded the approved use of Anktiva® (nogapendekin alfa inbakicept-pmln), given with Bacillus Calmette-Guérin (BCG), to include adults with high-grade papillary-only bladder cancer that has not spread into the bladder muscle and has not responded to BCG treatment. Anktiva® is the first FDA-approved treatment specifically for patients with BCG-unresponsive, high-grade papillary-only disease. <Read More>
Tecentriq® (atezolizumab) Injection – New Expanded Label – October 8, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. <Read More>
Tukysa® (tucatinib) Tablets – New Expanded Label – October 7, 2026 - Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved Tukysa® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. <Read More>
Rhapsido® (remibrutinib) Tablets – New Expanded Label – October 6, 2026 - Novartis announced that the U.S. Food and Drug Administration (FDA) approved Rhapsido® (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines. The approval represents an important advancement for people whose chronic hives and itch can be triggered by everyday skin friction, scratching, or rubbing. <Read More>
Jaypirca® (pirtobrutinib) Tablets – New Expanded Label – October 2, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted approval to Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. This FDA action expands the Jaypirca label to include patients earlier in their treatment course and also converts the December 2023 accelerated approval for later-line CLL/SLL to a traditional approval. <Read More>
Camzyos® (mavacamten) Capsules – New Expanded Label – September 30, 2026 - Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) approved Camzyos® (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more. Camzyos® now has the broadest indication of any cardiac myosin inhibitor (CMI). <Read More>
Gazyva® (obinutuzumab) – New Expanded Label – September 25, 2026 - Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), has received U.S. Food and Drug Administration (FDA) approval of Gazyva® (obinutuzumab) to reduce the risk of relapse in adult and pediatric patients 2 years of age and older with frequently relapsing or steroid dependent childhood-onset idiopathic nephrotic syndrome (INS) who are in complete remission. <Read More>
Olumiant® (baricitinib) Tablets – New Expanded Label – September 25, 2026 - Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Olumiant® (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe alopecia areata (AA). The approval expands Olumiant®’s U.S. label, building on its established use in adults with moderately to severely active rheumatoid arthritis and severe AA. AA is a chronic immune-mediated disease that causes unpredictable hair loss. <Read More>
Yusimry® (adalimumab-aqvh) Injection – New Expanded Label – September 25, 2026 - Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced that the U.S. Food and Drug Administration (“FDA”) has approved a high-concentration formulation (“HCF”) for Yusimry® (adalimumab-aqvh), as an interchangeable biosimilar to Humira. <Read More>
New Drug Shortage
November 16, 2026
Abacavir Sulfate Injection (Discontinuation)
Lamivudine Injection (Discontinuation)
Olipudase alfa-rpcp Injection (Currently in Shortage)
November 13, 2026
Bendamustine Hydrochloride Injection (Discontinuation)
Propranolol Hydrochloride Capsule, Extended Release (Discontinuation)
Somatropin Injection (Discontinuation)
Valrubicin Solution (Discontinuation)
November 6, 2026
Lincomycin Hydrochloride Injection (Discontinuation)
November 5, 2026
Tadalafil Tablet (Discontinuation)
October 30, 2026
Cefazolin in Dextrose Injection (Discontinuation)
Cefepime Hydrochloride Injection (Discontinuation)
Ceftriaxone Sodium Injection (Discontinuation)
Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension/Drops (Discontinuation)
Updated Drug Shortage
November 13, 2026
Hydroxocobalamin Injection (Currently in Shortage)
November 10, 2026
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Rocuronium Bromide Injection (Currently in Shortage)
November 9, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Etomidate Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Pentostatin Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
Sufentanil Citrate Injection (Currently in Shortage)
November 6, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Dexmedetomidine Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
November 4, 2026
Clonazepam Tablet (Resolved)
New Drug Recall and Safety Alerts
Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate Matter – November 9, 2026 - Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) to the hospital/healthcare facility/user level due to the presence of particulate matter identified as a glass particle inside the vial. <Read More>
Par Health Issues Voluntary Nationwide Recall of Argatroban Injection Due to the Presence of Particulate Matter – October 14, 2026 - Par Health is recalling 22 lots of Argatroban Injection 250 mg/2.5 mL (100 mg/mL) to the hospital/user level. This recall is being conducted due to the presence of particulate matter, identified as cellulose, polystyrene, polyethylene terephthalate, stopper material, and possibly stainless steel, that was detected in certain lots. <Read More>
Par Health Issues Voluntary Nationwide Recall of Two Lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) Due to the Presence of Particulate Matter – October 9, 2026 - Par Health is voluntarily recalling two lots of Brevital® Sodium 500 mg/vial CIV (Methohexital Sodium for Injection, USP) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose. <Read More>
Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels – October 1, 2026 – Greenwich RxExternal Link Disclaimer, a 503A compounding pharmacy, is voluntarily recalling specific lots of its compounded glutathione to the consumer level. The product is being recalled due to potential elevated endotoxin levels. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection – September 21, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
New Generic/Biosimilar Approval and Launch
Lucamzi™ (ranibizumab-blrz) Injection – New Lucentis® Biosimilar Approval – October 27, 2026 – Lucamzi™ (ranibizumab-blrz) biosimilar to Lucentis® has been approved by FDA in the US. Xbrane will finalize preparation for an upcoming launch of the product during 2027 together with its partners. <Read More>
Clinical and Pharmacy News
URGENT Notice to NCPDP Pharmacy Provider Members Using IINs (BINs) Recommendations to Address Risks with the Transition from the Six-Digit IIN (BIN) to Eight-Digit IIN (BIN) – This is a notification from the NCPDP Strategic National Implementation Process (SNIP) Committee to assist pharmacy provider stakeholders with the transition from the six-digit IIN (formerly known as BIN) to the eight-digit IIN. The compliance dates associated with several CMS final rules recently published set a more distinct timeline as to when various systems and processes should begin using the eight-digit IIN. Stakeholders are encouraged to review the information and recommendations below. Also reference other NCPDP resources to coordinate implementation timelines and mitigate transaction processing barriers. <Read More>
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin – November 16, 2026 – Modifications to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) for isotretinoin officially took effect November 15, 2026, introducing changes intended to reduce administrative burdens for patients, prescribers, and pharmacies while maintaining safeguards against fetal exposure to the medication. <Read More>
WHO Issues First Guidelines on Type 1 Diabetes for Adults – November 14, 2026 – More than 100 years after the discovery of insulin, many people living with type 1 diabetes still cannot access the insulin and care they need to survive. Type 1 diabetes is a lifelong condition in which the body does not produce enough insulin, making people dependent on daily insulin to survive. Marking World Diabetes Day 2026, the World Health Organization (WHO) has issued its first guidelines on the diagnosis and management of type 1 diabetes in adults, with recommendations designed to apply across all settings, including low-resource, emergency and humanitarian settings. <Read More>
AHA 2026: Pharmacists at the Center of Cardiometabolic Care – November 13, 2026 - When the American Heart Association (AHA) Scientific Sessions 2026 convened in Chicago, Illinois, from November 6 to 9, 2026, the data spanned a new class of incretin-based therapy, longer-term results for the first oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, blood pressure effects of an oral glucagon-like peptide-1 (GLP-1) receptor agonist, and real-world models of heart failure (HF) care. Across Pharmacy Times interviews and abstract coverage from the meeting, a common theme emerged: pharmacists are increasingly central to how new cardiometabolic therapies are titrated, monitored, and sustained. <Read More>
DOL Finalizes Pharmacy Benefit Manager Fee Disclosure Rule: What PBMs Must Disclose, and Should be Ready to Defend – November 4, 2026 – Pharmacy benefit managers (PBMs) that serve large, self-insured health plans will have to give employers a detailed account of how they are paid under a rule the U.S. Department of Labor (DOL) finalized on October 29, 2026. Employers will also have the right to audit that information. PBMs have time to prepare but should not wait. A PBM that wants to rely on the 90-day advance-notice benchmark for renewals will need its disclosures ready well before the rule applies. <Read More>
How the Biosimilars Access and Affordability Act Redefines IRA Delays – November 3, 2026 - Congress is again weighing changes to how the Inflation Reduction Act (IRA) treats biologics facing imminent biosimilar competition. The Biosimilars Access and Affordability Act (H.R. 10628/S. 5571), reintroduced in both the House and Senate, would create clearer criteria for delaying Medicare price negotiation of a reference biologic when a biosimilar is expected to reach the market while keeping the IRA’s 2-year maximum delay. Under the bill, manufacturers would certify their expected launch information, and if the biosimilar is not licensed and marketed within the 2-year period, the reference biologic would enter negotiation, and its manufacturer would owe rebates covering the delayed years. <Read More>
340B in the News
Protecting the 340B Program Means Protecting Patients First – November 13, 2026 – Every month roughly 30 patients at Third Street Health Center in Ohio pick up their prescriptions for about $6. Beginning in January, some of those same prescriptions could cost them more than $500. That is what a new federal rebate pilot program means for community health centers, the providers that use the 340B Drug Pricing Program exactly as Congress intended. Plenty has been written about the abuse of 340B, but CHCs are model stewards of the program and are required to reinvest any savings back into patient care. <Read More>
340B Cuts Softened, Site-Neutral Expansion Progresses in CMS CY 2027 OPPS Final Rule – November 5, 2026 - CMS finalized 340B drug reimbursement at ASP minus 28%, less than the proposed 33.4% cut, while accelerating the annual recoupment offset to 2% through 2031. The agency will reimburse imaging without contrast at grandfathered off-campus hospital outpatient departments at the Physician Fee Schedule equivalent, setting the rate at 40% of the standard OPPS rate. Hospitals will receive a net 2.3% payment update that industry advocates criticize as insufficient, alongside the removal of 637 services from the Inpatient Only list. <Read More>
Medicare Will Cut Billions From 340B, Expand Site-Neutral Payments in 2027 – November 5, 2026 - Medicare will slash payment rates for a federal drug discount program and broaden site-neutral policies next year, according to a final rule released by the CMS on Wednesday. 340B payments are set to drop by billions of dollars and Medicare will pay the same amount for more medical procedures, regardless if they’re furnished in hospital-owned outpatient departments. Under the final rule, hospital outpatient departments and ASCs will also see their Medicare payments increase 2.3% next year, slightly less than the 2.4% bump regulators proposed in July. <Read More>
Pharmacy Benefit Managers Take Savings Intended for 340B Providers Serving Vulnerable Patients – November 4, 2026 – A “pharmacy benefit manager” is a kind of middleman company that administers prescription drug benefits for insurers and employers, managing formularies, negotiating manufacturer rebates, processing claims, and overseeing pharmacy networks…But here’s how PBMs can legally steal every day from 340B safety-net nonprofit providers that Congress intended to invest back in services for vulnerable populations. Through corporate vertical integration, PBMs such as CVS Health, Express Scripts, and OptumRx own or control pharmacies participating in 340B, allowing them to capture portions of the drug-discount margin. Five major PBMs control 75% of 340B contract-pharmacy relationships, while more than half of contract-pharmacy 340B savings are going to CVS, which owns Aetna; Cigna, which owns Express Scripts; and United Healthcare, which owns Optum Rx. <Read More>
CMS Finalizes Increases to Medicare Hospital Outpatient Department Payment Rates, Changes to Site-Neutral and 340B for 2027 – November 4, 2026 – The Centers for Medicare & Medicaid Services Nov. 4 issued a final rule that increases Medicare hospital outpatient prospective payment system rates by a net 2.3% in calendar year 2027 compared to 2026. This includes a 3.2% market basket update, offset by a 0.9 percentage point cut for productivity. In a statement shared with the media, Ashley Thompson, AHA senior vice president of public policy analysis and development, said, “CMS’ Medicare outpatient hospital payment rate does not adequately take into account the financial challenges facing hospitals today. These challenges are amplified for hospitals serving rural and underserved communities, many of which are already making hard decisions about how they will maintain access to healthcare services in their communities.” <Read More>
Understanding the Origins of the 340B Drug Pricing Program – October 29, 2026 – Although nearly half of all U.S. hospitals participate in it, few Americans have heard of the 340B Drug Pricing Program. The program was designed to allow health care providers that serve low-income and uninsured patients, such as federally qualified health centers (FQHCs), to buy drugs from manufacturers at significant discounts to offset losses from uncompensated care. However, the program has grown significantly over time to include more than 60,000 clinical sites and accounts for more than $100 billion in discounted spending. Because discounted drugs can be used for all patients — not just those who cannot pay — providers participating in the program can generate revenue from billing discounted drugs to payers, including Medicaid, Medicare, and private insurance. Critics of the program have raised questions regarding hospitals’ use of revenue from the program. <Read More>
Manufacturer Notices to 340B Covered Entities
Clinical Insights: October 1, 2026
New Drug/Vaccine Approval
Atebrioz™ (zilurgisertib) Tablets – New Drug Approval – September 25, 2026 – The U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (bone formation outside the skeleton) in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended starting dosage is 100 mg orally once daily with or without food. <Read More>
Onswik™ (insulin efsitora alfa-gobe) Injection - New Drug Approval – September 24, 2026 – Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults with type 2 diabetes. Onswik™ is designed to deliver steady basal insulin levels over a full seven days. <Read More>
Lyrfigtu™ (lirafugratinib) Capsules – New Drug Approval – September 23, 2026 – The Food and Drug Administration approved lirafugratinib (Lyrfigtu™, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. <Read More>
Fayuvi™ (rebisufligene etisparvovec-hopf) Suspension for Intravenous Infusion - formerly UX111 – New Drug Approval – September 17, 2026 – The U.S. Food and Drug Administration approved Fayuvi™ (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A., MPS IIIA is a rare inherited disease that progressively damages the brain and nervous system, causing children to lose cognitive, language and other developmental abilities over time. Until now, treatment was limited to managing symptoms; there was no FDA-approved therapy designed to change the underlying course of the disease. <Read More>
Bexlutry™ (lutetium Lu 177 dotatate) Injection – New Drug Approval – September 14, 2026 – Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Bexlutry™ lutetium Lu 177 dotatate injection for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. <Read More>
Pixclara® (floretyrosine F 18) Injection – New Drug Approval – September 11, 2026 – Telix announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer). <Read More>
Isembyld™ (apitegromab-mstn) Injection – New Drug Approval – September 11, 2026 – Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, announced that the FDA has approved Isembyld™ (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. <Read More>
Etcamah™ (camizestrant) Tablets – New Drug Approval – September 4, 2026 – The Food and Drug Administration granted accelerated approval to camizestrant (Etcamah™, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test. <Read More>
Zanvastro™ (zilganersen) Injection – New Drug Approval – September 3, 2026 – The U.S. Food and Drug Administration has approved Zanvastro™ (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro™ is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease. <Read More>
Omcazio™ (cabozantinib) Capsules – New Drug Approval – September 3, 2026 – Handa Pharmaceuticals, Inc. (“Handa” or the “Company”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted final approval to Omcazio™ (cabozantinib) capsules, the lauryl sulfate salt formulation of cabozantinib developed by the Company’s U.S. subsidiary, Handa Oncology, LLC. The action converts Handa’s prior tentative approval to final approval and authorizes Omcazio™ for commercialization in the United States. <Read More>
Mimrylo™ (rusfertide) Lyophilized Powder for Injection – New Drug Approval – August 28, 2026 – Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for Mimrylo™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. <Read More>
Bixlenvo™ (bictegravir and lenacapavir) Tablets – New Drug Approval – August 27, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo™ is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. <Read More>
Lisraya™ (brepocitinib) Tablets – New Drug Approval – August 27, 2026 - The U.S. Food and Drug Administration has approved Lisraya™ (brepocitinib) tablets for the treatment of dermatomyositis in adults. For decades, dermatomyositis patients have had limited treatment options to manage their symptoms. The approval of Lisraya™ offers patients an important new alternative by providing an effective oral treatment option. <Read More>
Rasonque™ (daraxonrasib) Tablets – New Drug Approval – August 26, 2026 – The U.S. Food and Drug Administration approved Rasonque™ (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. <Read More>
New Label Expansions
Welireg® (belzutifan) Tablets – New Expanded Label – September 24, 2026 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of Welireg® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. <Read More>
Aqneursa® (levacetylleucine) Granules for Oral Suspension – New Expanded Label – September 18, 2026 – The U.S. Food and Drug Administration has approved Aqneursa® (levacetylleucine) for oral suspension to treat ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg (about 33 pounds). Aqneursa® was previously approved in 2024 to treat the neurological manifestations of Niemann-Pick disease type C. This approval makes Aqneursa® the first treatment approved for ataxia in patients with ataxia-telangiectasia. <Read More>
Kerendia® (finerenone) Tablets – New Expanded Label – September 17, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) approved Kerendia® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (sNDA). <Read More>
Ibtrozi® (taletrectinib) Capsules – New Expanded Label – September 16, 2026 – Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Ibtrozi® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). <Read More>
Inluriyo® (imlunestrant) Tablets – New Expanded Label – September 16, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo® (imlunestrant), an oral estrogen receptor (ER) antagonist, in combination with Verzenio® (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated locally advanced or metastatic breast cancer (MBC), as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Joenja® (leniolisib) Tablets – New Expanded Label – September 11, 2026 – FDA has approved Joenja® (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children 4-11 years who weigh at least 27 kg. Joenja® was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day. Children 4-11 years take a weight-based dosage (40, 50, or 70 mg) orally twice a day, approximately 12 hours apart. <Read More>
Imdelltra® (tarlatamab-dlle) for Injection – New Expanded Label – September 11, 2026 – Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved an update to the Imdelltra® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting. This approval means that patients receiving Imdelltra® should now be monitored for 6 to 8 hours from the start of their first two infusions, compared with the previously recommended 22 to 24 hours. <Read More>
Ameluz® (aminolevulinic acid) Gel – New Expanded Label – September 9, 2026 – Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults. <Read More>
Hyrnuo® (sevabertinib) Tablets – New Expanded Label – September 9, 2026 – The Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo®, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. <Read More>
Stelara® (ustekinumab) Injection – New Expanded Label – August 28, 2026 – The U.S. Food and Drug Administration has approved Stelara® (ustekinumab) injection for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients aged 2 years old and older. On April 15, 2026, Stelara® was approved for the treatment of moderately to severely active Crohn’s disease (CD) in pediatric patients aged 2 years old and older. Stelara® is the first approved therapeutic monoclonal antibody that does not target human tumor necrosis factor alpha (TNFα) for the two main forms of pediatric inflammatory bowel disease. <Read More>
Besremi® (ropeginterferon alfa-2b-njft) Injection – New Expanded Label – August 28, 2026 – PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) announced the U.S. Food and Drug Administration (FDA) has approved Besremi® (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades. Besremi® has been approved for adults with ET, regardless of their genotype or disease status, including newly diagnosed patients who are naive to cytoreductive therapy. <Read More>
Spikevax® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. <Read More>
Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted) Injectable Suspension – August 27, 2026 – Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan. These approvals position Novavax to continue earning royalties on net sales in these markets this season. <Read More>
Comirnaty® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (Comirnaty® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. <Read More>
Mounjaro® (tirzepatide) Injection – New Expanded Label – August 27, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro® (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. <Read More>
Tevimbra® (tislelizumab-jsgr) Injection – New Expanded Label – August 25, 2026 – BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Tevimbra® (tislelizumab) in combination with Ziihera® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). <Read More>
New Drug Shortage
September 21, 2026
Arsenic Trioxide Injection (Discontinuation)
September 18, 2026
Rivaroxaban For Suspension (Discontinuation)
Rivastigmine Film, Extended Release (Discontinuation)
September 16, 2026
Melphalan Hydrochloride Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
September 11, 2026
Cisatracurium Besylate Injection (Discontinuation)
Micafungin Sodium Injection (Discontinuation)
September 10, 2026
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution (Discontinuation)
Updated Drug Shortage
September 22, 2026
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
September 21, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
September 18, 2026
Bumetanide Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Oral Solution (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Lisdexamfetamine Dimesylate Tablet, Chewable (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Methylphenidate Hydrochloride Tablet, Extended Release (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Promethazine Hydrochloride Injection (Currently in Shortage)
Technetium TC-99M Pyrophosphate Kit Injection (Currently in Shortage)
September 17, 2026
Carboplatin Injection (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Dextrose Monohydrate 70% Injection (Currently in Shortage)
Ifosfamide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
September 16, 2026
Desmopressin Acetate Spray (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Streptozocin Powder, For Solution (Currently in Shortage)
New Drug Recall and Safety Alerts
Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection – September 18, 2026 - Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose or stopper material. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP – September 17, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container – September 3, 2026 - B. Braun Medical Inc (B. Braun) is voluntarily recalling three (3) lots of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container, to the hospital/healthcare facility/user level due to presence of particulate matter identified as iron oxide, inorganic, cellulose or polystyrene particulate matter. <Read More>
Baxter Issues Voluntary Nationwide Recall for Two Lots of 0.9% Sodium Chloride Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling two lots of 0.9% Sodium Chloride Injection due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of 70% Dextrose Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution. <Read More>
New Generic/Biosimilar Approval and Launch
Bravnetsa™ (lutetium Lu 177 dotatate) Injection – New Lutathera® Biosimilar Approval – September 21, 2026 – Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Bravnetsa™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera® (lutetium Lu 177 dotatate). <Read More>
Clinical and Pharmacy News
Navigating GLP-1 Switches: A Guide for Primary Care – September 29, 2026 - As GLP-1 receptor agonists and dual incretin agents become more common in treating obesity and type 2 diabetes, primary care providers are handling more medication switches. The reason may be insurance coverage, ongoing gastrointestinal side effects, inadequate response, or the need for better blood sugar control or weight support. Whatever the driver, switching is not simply trading one prescription for another. It requires planning around half-lives, dose history, side effects, and the risk for blood sugar swings. <Read More>
Insurance Coverage Lags as Cancer Science, Treatment Move Forward – September 24, 2026 - Eighteen months after his initial diagnosis, chemotherapy hadn’t slowed 21-year-old Mason Henderson’s rare brain tumor, which had spread to his spinal fluid. So, he left his home in southeastern Texas to spend three weeks in a clinical trial in New York City. But that failed, too, leaving a murky path for Henderson, whose cancer was so rare the World Health Organization had only given it a name in 2021. So early this year, Henderson’s doctors, evaluating his tumor’s deep genetic language, turned to a drug made by Merck and AstraZeneca called Lynparza®. <Read More>
Cholesterol Control Gets Personalized—How New Guidelines Tailor Treatment to Your Unique Risk Profile – September 24, 2026 – As a cardiologist with expertise in sports and exercise science, I routinely care for patients who want to make healthy lifestyle choices to control their cholesterol levels, reduce their risk of cardiovascular disease and improve their overall health. In March 2026, the American Heart Association and the American College of Cardiology issued new guidelines on how to treat dyslipidemia. The guidelines, last updated in 2018, incorporate findings from several new studies on how to more effectively treat—and prevent—the condition. The new guidelines can help doctors personalize treatment to reduce each patient's risk of developing cardiovascular disease. <Read More>
VA/DoD Release Updated Tobacco Cessation Clinical Practice Guidelines – September 22, 2026 - The US Department of Veterans Affairs (VA) and Department of Defense (DoD) have released an updated clinical practice guideline recommending varenicline or combination nicotine replacement therapy as the preferred treatments for tobacco cessation, according to a synopsis published in Annals of Internal Medicine. The updated guidance addresses nicotine and tobacco use among service members and veterans, noting that use leads to adverse physical and mental health effects, and reduces military force readiness. For respiratory therapists and allied healthcare professionals treating patients with chronic lung conditions and nicotine dependence, the document outlines practical strategies to improve long-term abstinence rates. <Read More>
Generic Drug Costs Burdening Patients as Much as Brand Name Options – September 18, 2026 - Aggregate OOP burden for generics exceeds brands due to utilization intensity, especially among Medicare beneficiaries with higher generic fill counts and near-parity annual OOP spending versus brands. Cost-related nonadherence remains substantial, with reported treatment abandonment and dose modification, positioning community pharmacists as key actors in mitigating downstream acute-care utilization. <Read More>
Specialty Pharmacy Leaders to Convene for NASP inSPire2026 – September 18, 2026 - As specialty pharmacy addresses the rising cost and complexity of cell and gene therapies, this year's newly rebranded inSPire2026 meeting will bring pharmacists, nurses, and industry leaders together to chart how those breakthroughs actually reach patients. From September 22 to 25, 2026, specialty pharmacy professionals gathered for inSPire2026, the newly rebranded successor to the National Association of Specialty Pharmacy's (NASP) Annual Meeting & Expo. <Read More>
340B in the News
340B Hospitals Lag Behind Peers in Charity Care Spending: Report – September 25, 2026 - A new report from a conservative think tank is accusing 340B hospitals of providing less charity care than other nonprofit hospitals, despite receiving discounted drugs. Hospitals participating in the 340B drug discount program spent 2.16% of their operating expenses on free or discounted care for low-income patients, called charity care, compared with 2.82% at non-340B hospitals, according to a Thursday analysis from the Pioneer Institute and CancerCare. <Read More>
What the Revised 340B Rebate Pilot Programme Means for Pharma Revenue Operations – September 24, 2026 - The US government's revised 340B rebate pilot programme signals that pharmaceutical manufacturers need to prepare their operations for the next phase of drug discount management. The pilot shifts how pharmaceutical manufacturers provide 340B discounts to eligible hospitals and healthcare providers. The savings for certain medications will now come in the form of rebates, rather than upfront discounts. Under this new arrangement, covered entities must purchase selected Medicare negotiation drugs at the wholesale acquisition cost (WAC) or negotiated prices, then seek a manufacturer refund for the difference to the 340B price. <Read More>
The 340B Debate Can’t Ignore Supply Chain Realities – September 23, 2026 - Healthcare distributors deliver roughly 15 million medicines and healthcare products every day to hospitals, physicians’ offices, pharmacies, and other providers across the country. While they play a critical role in keeping the healthcare supply chain moving, they are largely removed from the design and operation of the 340B Drug Pricing Program. As lawmakers debate changes to 340B, it is essential to recognize the distinct role distributors serve — and avoid policies that assign them responsibility for decisions they do not control. <Read More>
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data – September 18, 2026 - Johnson & Johnson now requires comprehensive pharmacy/medical claims elements to be submitted to its 340B ESP platform, with suspension of all 340B pricing within five business days after repeated noncompliance. Eli Lilly’s January 2026 policy expanded reporting to in-house dispensing and provider-administered drugs, enforcing 45–60 day deadlines and threatening termination, with suspensions already prompting litigation. <Read More>
Utilizing 340B Margin to Create a Patient Prescription Assistance Program – September 16, 2026 - Medicaid work/volunteer/school hour verification and 6-month renewals may drive coverage losses, disrupting continuity and access to specialty drugs among adults aged 19 to 64 years in expansion populations. Manufacturer restrictions on 340B pricing and claims-submission requirements add administrative burden and risk multimillion-dollar annual acquisition-cost increases for noncompliant safety-net health systems. Hospital-owned specialty pharmacies can fund PAPs with 340B savings to lower patient cost exposure, improve adherence, reduce abandonment, and mitigate reliance on external subsidies or foundations. <Read More>
Clinical Insights: October 1, 2026
New Drug/Vaccine Approval
Atebrioz™ (zilurgisertib) Tablets – New Drug Approval – September 25, 2026 – The U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (bone formation outside the skeleton) in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended starting dosage is 100 mg orally once daily with or without food. <Read More>
Onswik™ (insulin efsitora alfa-gobe) Injection - New Drug Approval – September 24, 2026 – Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults with type 2 diabetes. Onswik™ is designed to deliver steady basal insulin levels over a full seven days. <Read More>
Lyrfigtu™ (lirafugratinib) Capsules – New Drug Approval – September 23, 2026 – The Food and Drug Administration approved lirafugratinib (Lyrfigtu™, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. <Read More>
Fayuvi™ (rebisufligene etisparvovec-hopf) Suspension for Intravenous Infusion - formerly UX111 – New Drug Approval – September 17, 2026 – The U.S. Food and Drug Administration approved Fayuvi™ (rebisufligene etisparvovec-hopf), the first treatment for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A., MPS IIIA is a rare inherited disease that progressively damages the brain and nervous system, causing children to lose cognitive, language and other developmental abilities over time. Until now, treatment was limited to managing symptoms; there was no FDA-approved therapy designed to change the underlying course of the disease. <Read More>
Bexlutry™ (lutetium Lu 177 dotatate) Injection – New Drug Approval – September 14, 2026 – Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Bexlutry™ lutetium Lu 177 dotatate injection for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. <Read More>
Pixclara® (floretyrosine F 18) Injection – New Drug Approval – September 11, 2026 – Telix announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer). <Read More>
Isembyld™ (apitegromab-mstn) Injection – New Drug Approval – September 11, 2026 – Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, announced that the FDA has approved Isembyld™ (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children two years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment. <Read More>
Etcamah™ (camizestrant) Tablets – New Drug Approval – September 4, 2026 – The Food and Drug Administration granted accelerated approval to camizestrant (Etcamah™, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test. <Read More>
Zanvastro™ (zilganersen) Injection – New Drug Approval – September 3, 2026 – The U.S. Food and Drug Administration has approved Zanvastro™ (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro™ is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease. <Read More>
Omcazio™ (cabozantinib) Capsules – New Drug Approval – September 3, 2026 – Handa Pharmaceuticals, Inc. (“Handa” or the “Company”) (TSE:6620) announced that the U.S. Food and Drug Administration (“FDA”) has granted final approval to Omcazio™ (cabozantinib) capsules, the lauryl sulfate salt formulation of cabozantinib developed by the Company’s U.S. subsidiary, Handa Oncology, LLC. The action converts Handa’s prior tentative approval to final approval and authorizes Omcazio™ for commercialization in the United States. <Read More>
Mimrylo™ (rusfertide) Lyophilized Powder for Injection – New Drug Approval – August 28, 2026 – Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA) for Mimrylo™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. <Read More>
Bixlenvo™ (bictegravir and lenacapavir) Tablets – New Drug Approval – August 27, 2026 – Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo™ is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. <Read More>
Lisraya™ (brepocitinib) Tablets – New Drug Approval – August 27, 2026 - The U.S. Food and Drug Administration has approved Lisraya™ (brepocitinib) tablets for the treatment of dermatomyositis in adults. For decades, dermatomyositis patients have had limited treatment options to manage their symptoms. The approval of Lisraya™ offers patients an important new alternative by providing an effective oral treatment option. <Read More>
Rasonque™ (daraxonrasib) Tablets – New Drug Approval – August 26, 2026 – The U.S. Food and Drug Administration approved Rasonque™ (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. <Read More>
New Label Expansions
Welireg® (belzutifan) Tablets – New Expanded Label – September 24, 2026 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced the U.S. Food and Drug Administration (FDA) has approved the dual oral regimen of Welireg® (belzutifan), Merck’s first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, plus Lenvima® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of adult patients with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor. <Read More>
Aqneursa® (levacetylleucine) Granules for Oral Suspension – New Expanded Label – September 18, 2026 – The U.S. Food and Drug Administration has approved Aqneursa® (levacetylleucine) for oral suspension to treat ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg (about 33 pounds). Aqneursa® was previously approved in 2024 to treat the neurological manifestations of Niemann-Pick disease type C. This approval makes Aqneursa® the first treatment approved for ataxia in patients with ataxia-telangiectasia. <Read More>
Kerendia® (finerenone) Tablets – New Expanded Label – September 17, 2026 – Bayer announced that the U.S. Food and Drug Administration (FDA) approved Kerendia® (finerenone) to reduce urinary albumin-to-creatinine ratio (UACR), which is expected to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline and end-stage kidney disease in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), following the agency’s Priority Review of the supplemental New Drug Application (sNDA). <Read More>
Ibtrozi® (taletrectinib) Capsules – New Expanded Label – September 16, 2026 – Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Ibtrozi® (taletrectinib), a ROS1 inhibitor approved for the treatment of locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). <Read More>
Inluriyo® (imlunestrant) Tablets – New Expanded Label – September 16, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Inluriyo® (imlunestrant), an oral estrogen receptor (ER) antagonist, in combination with Verzenio® (abemaciclib), a CDK4/6 inhibitor, for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated locally advanced or metastatic breast cancer (MBC), as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Joenja® (leniolisib) Tablets – New Expanded Label – September 11, 2026 – FDA has approved Joenja® (leniolisib) tablets as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in children 4-11 years who weigh at least 27 kg. Joenja® was first approved in 2023 for the same indication in patients 12 years and older at a dose of 70 mg orally twice a day. Children 4-11 years take a weight-based dosage (40, 50, or 70 mg) orally twice a day, approximately 12 hours apart. <Read More>
Imdelltra® (tarlatamab-dlle) for Injection – New Expanded Label – September 11, 2026 – Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved an update to the Imdelltra® (tarlatamab-dlle) Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in an appropriate healthcare setting. This approval means that patients receiving Imdelltra® should now be monitored for 6 to 8 hours from the start of their first two infusions, compared with the previously recommended 22 to 24 hours. <Read More>
Ameluz® (aminolevulinic acid) Gel – New Expanded Label – September 9, 2026 – Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental New Drug Application (sNDA) for Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults. <Read More>
Hyrnuo® (sevabertinib) Tablets – New Expanded Label – September 9, 2026 – The Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo®, Bayer HealthCare Pharmaceuticals Inc.), a kinase inhibitor, for adults with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. <Read More>
Stelara® (ustekinumab) Injection – New Expanded Label – August 28, 2026 – The U.S. Food and Drug Administration has approved Stelara® (ustekinumab) injection for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients aged 2 years old and older. On April 15, 2026, Stelara® was approved for the treatment of moderately to severely active Crohn’s disease (CD) in pediatric patients aged 2 years old and older. Stelara® is the first approved therapeutic monoclonal antibody that does not target human tumor necrosis factor alpha (TNFα) for the two main forms of pediatric inflammatory bowel disease. <Read More>
Besremi® (ropeginterferon alfa-2b-njft) Injection – New Expanded Label – August 28, 2026 – PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446) announced the U.S. Food and Drug Administration (FDA) has approved Besremi® (ropeginterferon alfa-2b-njft) for the treatment of adults with essential thrombocythemia (ET), making it the first new FDA-approved treatment for ET in nearly three decades. Besremi® has been approved for adults with ET, regardless of their genotype or disease status, including newly diagnosed patients who are naive to cytoreductive therapy. <Read More>
Spikevax® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. <Read More>
Nuvaxovid™ (COVID-19 Vaccine, Adjuvanted) Injectable Suspension – August 27, 2026 – Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan. These approvals position Novavax to continue earning royalties on net sales in these markets this season. <Read More>
Comirnaty® (COVID-19 Vaccine, mRNA) Injection – New Expanded Label – August 27, 2026 – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies’ 2026-2027 COVID-19 vaccine formula targeting the XFG variant (Comirnaty® XFG; COVID-19 Vaccine, mRNA) for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. <Read More>
Mounjaro® (tirzepatide) Injection – New Expanded Label – August 27, 2026 – Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Mounjaro® (tirzepatide), a dual GIP and GLP-1 hormone receptor agonist, to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. <Read More>
Tevimbra® (tislelizumab-jsgr) Injection – New Expanded Label – August 25, 2026 – BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Tevimbra® (tislelizumab) in combination with Ziihera® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). <Read More>
New Drug Shortage
September 21, 2026
Arsenic Trioxide Injection (Discontinuation)
September 18, 2026
Rivaroxaban For Suspension (Discontinuation)
Rivastigmine Film, Extended Release (Discontinuation)
September 16, 2026
Melphalan Hydrochloride Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
September 11, 2026
Cisatracurium Besylate Injection (Discontinuation)
Micafungin Sodium Injection (Discontinuation)
September 10, 2026
Dextrose Monohydrate, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride Solution (Discontinuation)
Updated Drug Shortage
September 22, 2026
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Carboplatin Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Heparin Sodium Injection (Currently in Shortage)
Hydromorphone Hydrochloride Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Lorazepam Injection (Currently in Shortage)
Midazolam Hydrochloride Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Sodium Bicarbonate Injection (Currently in Shortage)
September 21, 2026
Clindamycin Phosphate Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
September 18, 2026
Bumetanide Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Fentanyl Citrate Injection (Currently in Shortage)
Furosemide Oral Solution (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Lisdexamfetamine Dimesylate Tablet, Chewable (Currently in Shortage)
Methotrexate Sodium Injection (Currently in Shortage)
Methylphenidate Hydrochloride Tablet, Extended Release (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Morphine Sulfate Injection (Currently in Shortage)
Promethazine Hydrochloride Injection (Currently in Shortage)
Technetium TC-99M Pyrophosphate Kit Injection (Currently in Shortage)
September 17, 2026
Carboplatin Injection (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Dextrose Monohydrate 10% Injection (Currently in Shortage)
Dextrose Monohydrate 5% Injection (Currently in Shortage)
Dextrose Monohydrate 70% Injection (Currently in Shortage)
Ifosfamide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
September 16, 2026
Desmopressin Acetate Spray (Currently in Shortage)
Lisdexamfetamine Dimesylate Capsule (Currently in Shortage)
Streptozocin Powder, For Solution (Currently in Shortage)
New Drug Recall and Safety Alerts
Par Health Issues Voluntary Nationwide Recall of Two Lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection – September 18, 2026 - Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) to the hospital level. The product is being recalled due to the presence of particulate matter identified as cellulose or stopper material. <Read More>
Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP – September 17, 2026 - Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% Sodium Chloride Injection, USP, 100mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% Sodium Chloride Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be Potassium Chloride Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. <Read More>
B. Braun Medical Inc. Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container – September 3, 2026 - B. Braun Medical Inc (B. Braun) is voluntarily recalling three (3) lots of 0.9% Sodium Chloride Injection USP, 100 mL, in a 150 mL PAB® Container, to the hospital/healthcare facility/user level due to presence of particulate matter identified as iron oxide, inorganic, cellulose or polystyrene particulate matter. <Read More>
Baxter Issues Voluntary Nationwide Recall for Two Lots of 0.9% Sodium Chloride Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling two lots of 0.9% Sodium Chloride Injection due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of Anticoagulant Sodium Citrate Solution – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of Anticoagulant Sodium Citrate Solution due to the potential presence of particulate matter identified as fiberglass in the solution. <Read More>
Baxter Issues Voluntary Nationwide Recall for One Lot of 70% Dextrose Injection – August 25, 2026 - Baxter International Inc. (NYSE:BAX) is voluntarily recalling one lot of 70% Dextrose Injection due to the potential presence of particulate matter identified as stainless steel particles in the solution. <Read More>
New Generic/Biosimilar Approval and Launch
Bravnetsa™ (lutetium Lu 177 dotatate) Injection – New Lutathera® Biosimilar Approval – September 21, 2026 – Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that the U.S. Food and Drug Administration (FDA) has granted final approval for Bravnetsa™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to Lutathera® (lutetium Lu 177 dotatate). <Read More>
Clinical and Pharmacy News
Navigating GLP-1 Switches: A Guide for Primary Care – September 29, 2026 - As GLP-1 receptor agonists and dual incretin agents become more common in treating obesity and type 2 diabetes, primary care providers are handling more medication switches. The reason may be insurance coverage, ongoing gastrointestinal side effects, inadequate response, or the need for better blood sugar control or weight support. Whatever the driver, switching is not simply trading one prescription for another. It requires planning around half-lives, dose history, side effects, and the risk for blood sugar swings. <Read More>
Insurance Coverage Lags as Cancer Science, Treatment Move Forward – September 24, 2026 - Eighteen months after his initial diagnosis, chemotherapy hadn’t slowed 21-year-old Mason Henderson’s rare brain tumor, which had spread to his spinal fluid. So, he left his home in southeastern Texas to spend three weeks in a clinical trial in New York City. But that failed, too, leaving a murky path for Henderson, whose cancer was so rare the World Health Organization had only given it a name in 2021. So early this year, Henderson’s doctors, evaluating his tumor’s deep genetic language, turned to a drug made by Merck and AstraZeneca called Lynparza®. <Read More>
Cholesterol Control Gets Personalized—How New Guidelines Tailor Treatment to Your Unique Risk Profile – September 24, 2026 – As a cardiologist with expertise in sports and exercise science, I routinely care for patients who want to make healthy lifestyle choices to control their cholesterol levels, reduce their risk of cardiovascular disease and improve their overall health. In March 2026, the American Heart Association and the American College of Cardiology issued new guidelines on how to treat dyslipidemia. The guidelines, last updated in 2018, incorporate findings from several new studies on how to more effectively treat—and prevent—the condition. The new guidelines can help doctors personalize treatment to reduce each patient's risk of developing cardiovascular disease. <Read More>
VA/DoD Release Updated Tobacco Cessation Clinical Practice Guidelines – September 22, 2026 - The US Department of Veterans Affairs (VA) and Department of Defense (DoD) have released an updated clinical practice guideline recommending varenicline or combination nicotine replacement therapy as the preferred treatments for tobacco cessation, according to a synopsis published in Annals of Internal Medicine. The updated guidance addresses nicotine and tobacco use among service members and veterans, noting that use leads to adverse physical and mental health effects, and reduces military force readiness. For respiratory therapists and allied healthcare professionals treating patients with chronic lung conditions and nicotine dependence, the document outlines practical strategies to improve long-term abstinence rates. <Read More>
Generic Drug Costs Burdening Patients as Much as Brand Name Options – September 18, 2026 - Aggregate OOP burden for generics exceeds brands due to utilization intensity, especially among Medicare beneficiaries with higher generic fill counts and near-parity annual OOP spending versus brands. Cost-related nonadherence remains substantial, with reported treatment abandonment and dose modification, positioning community pharmacists as key actors in mitigating downstream acute-care utilization. <Read More>
Specialty Pharmacy Leaders to Convene for NASP inSPire2026 – September 18, 2026 - As specialty pharmacy addresses the rising cost and complexity of cell and gene therapies, this year's newly rebranded inSPire2026 meeting will bring pharmacists, nurses, and industry leaders together to chart how those breakthroughs actually reach patients. From September 22 to 25, 2026, specialty pharmacy professionals gathered for inSPire2026, the newly rebranded successor to the National Association of Specialty Pharmacy's (NASP) Annual Meeting & Expo. <Read More>
340B in the News
340B Hospitals Lag Behind Peers in Charity Care Spending: Report – September 25, 2026 - A new report from a conservative think tank is accusing 340B hospitals of providing less charity care than other nonprofit hospitals, despite receiving discounted drugs. Hospitals participating in the 340B drug discount program spent 2.16% of their operating expenses on free or discounted care for low-income patients, called charity care, compared with 2.82% at non-340B hospitals, according to a Thursday analysis from the Pioneer Institute and CancerCare. <Read More>
What the Revised 340B Rebate Pilot Programme Means for Pharma Revenue Operations – September 24, 2026 - The US government's revised 340B rebate pilot programme signals that pharmaceutical manufacturers need to prepare their operations for the next phase of drug discount management. The pilot shifts how pharmaceutical manufacturers provide 340B discounts to eligible hospitals and healthcare providers. The savings for certain medications will now come in the form of rebates, rather than upfront discounts. Under this new arrangement, covered entities must purchase selected Medicare negotiation drugs at the wholesale acquisition cost (WAC) or negotiated prices, then seek a manufacturer refund for the difference to the 340B price. <Read More>
The 340B Debate Can’t Ignore Supply Chain Realities – September 23, 2026 - Healthcare distributors deliver roughly 15 million medicines and healthcare products every day to hospitals, physicians’ offices, pharmacies, and other providers across the country. While they play a critical role in keeping the healthcare supply chain moving, they are largely removed from the design and operation of the 340B Drug Pricing Program. As lawmakers debate changes to 340B, it is essential to recognize the distinct role distributors serve — and avoid policies that assign them responsibility for decisions they do not control. <Read More>
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data – September 18, 2026 - Johnson & Johnson now requires comprehensive pharmacy/medical claims elements to be submitted to its 340B ESP platform, with suspension of all 340B pricing within five business days after repeated noncompliance. Eli Lilly’s January 2026 policy expanded reporting to in-house dispensing and provider-administered drugs, enforcing 45–60 day deadlines and threatening termination, with suspensions already prompting litigation. <Read More>
Utilizing 340B Margin to Create a Patient Prescription Assistance Program – September 16, 2026 - Medicaid work/volunteer/school hour verification and 6-month renewals may drive coverage losses, disrupting continuity and access to specialty drugs among adults aged 19 to 64 years in expansion populations. Manufacturer restrictions on 340B pricing and claims-submission requirements add administrative burden and risk multimillion-dollar annual acquisition-cost increases for noncompliant safety-net health systems. Hospital-owned specialty pharmacies can fund PAPs with 340B savings to lower patient cost exposure, improve adherence, reduce abandonment, and mitigate reliance on external subsidies or foundations. <Read More>
Clinical Insights: August 27, 2026
New Drug/Vaccine Approval
Pasatru™ (garetosmab-grts) Injection – New Drug Approval – August 19, 2026 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Recognizing the significant mobility challenges faced by many people with FOP, Pasatru can be administered across a range of care settings, including home infusion where appropriate. <Read More>
Genglycos™ (pariglasgene brecaparvovec-opnr) Suspension for Intravenous Infusion - formerly DTX401 – New Drug Approval – August 19, 2026 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Genglycos™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). <Read More>
Zenbexus™ (iberdomide) Capsules – New Drug Approval – August 13, 2026 - The Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus™, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. <Read More>
Tauklarify™ (florquinitau F 18) Injection - formerly MK-6240 – New Drug Approval – August 13, 2026 - Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced U.S. Food and Drug Administration (FDA) approval of Tauklarify™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease to identify patients with tau neurofibrillary tangle (NFT) pathology. <Read More>
Tudriqev™ (vusolimogene oderparepvec-wtpg) Suspension for Intratumor Injection – New Drug Approval – August 6, 2026 - The Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev™, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. <Read More>
Orzeyful™ (oveporexton) Tablets – New Drug Approval – August 5, 2026 - Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved Orzeyful™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. <Read More>
mFLUSIVA® (influenza vaccine, mRNA) Injection - formerly mRNA-1010 – New Drug Approval – August 5, 2026 - Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA® – for adults 50 years of age and older. <Read More>
Gwyn Lo™ (ethinyl estradiol and norelgestromin) Transdermal System – New Drug Approval – July 28, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo™ is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m® who are appropriate candidates for CHC. The Gwyn Lo™ dosage is norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. <Read More>
New Label Expansions
Imaavy® (nipocalimab-aahu) Injection – New Expanded Label – August 24, 2026 – Johnson & Johnson (NYSE: JNJ) announced the U.S. Food and Drug Administration (FDA) approval of Imaavy® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. <Read More>
Lerochol® (lerodalcibep-liga) Injection - New Expanded Label – August 13, 2026 – LIB Therapeutics, Inc. (LIB)… announced the U.S. Food and Drug Administration (FDA) has approved an autoinjector for Lerochol® (lerodalcibep-liga) Injection 300 mg/1.2 mL, a third-generation Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor that combines robust and sustained efficacy with once-monthly, single injection self-administration to support long-term adherence. <Read More>
Pluvicto® (lutetium lu 177 vipivotide tetraxetan) Injection - New Expanded Label – July 31, 2026 - Novartis announced the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer (mHSPC). <Read More>
New Drug Shortage
August 25, 2026
Liraglutide Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
August 24, 2026
Disopyramide Phosphate Capsule, Extended Release (Discontinuation)
August 14, 2026
Fulvestrant Injection (Discontinuation)
August 13, 2026
Diclofenac Sodium Tablet, Delayed Release (Discontinuation)
Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution (Discontinuation)
August 10, 2026
Glyburide Tablet (Discontinuation)
Updated Drug Shortage
August 25, 2026
Dexamethasone Sodium Phosphate Injection (Currently in Shortage)
Liraglutide Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
August 24, 2026
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Desmopressin Acetate Spray (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
August 21, 2026
Bumetanide Injection (Currently in Shortage)
August 20, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
August 18, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Metronidazole Injection (Currently in Shortage)
Rifampin Capsule (Currently in Shortage)
New Drug Recall and Safety Alerts
Thyroid Tablets, USP 30 mg by Vitruvias Therapeutics, Inc – New Voluntary Recall – August 21, 2026 - Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent. <Read More>
Glutathione 200 mg/mL Multi-Dose Vials by Optimal Balance Pharmacy – New Voluntary Recall – August 19, 2026 - Optimal Balance Pharmacy is voluntarily recalling one lot of Compounded Glutathione 200 MG/ML 30 ML Multi-Dose Vials to the patient level. The product is being recalled because pharmacy testing identified elevated bacterial endotoxin levels. <Read More>
Excel® Lactated Ringers Injection, 1000mL by B. Braun Medical Inc. – New Voluntary Recall – August 19, 2026 - B. Braun Medical Inc (B. Braun), is voluntarily recalling one lot of Excel® Lactated Ringers Injection, 1000mL to the hospital/healthcare facility level, due to the presence of particulate matter in solution identified primarily as cellulose cotton fibers, with individual particles also identified as cellulose wood fiber and polystyrene. <Read More>
Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials by Fresenius Kabi – New Voluntary Recall – August 10, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. <Read More>
Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe by Fresenius Kabi – New Voluntary Recall – August 4, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist® – 2 mg/1 mL due to a label mix-up. The MicroVault labeled as morphine 2 mg/1 mL, may contain a Prefilled Syringe of Dilaudid® – 0.5 mg/0.5 mL. This recall is being conducted to the user level. <Read More>
Optiray® Imaging Bulk Package - 350, 500mL, Vial by Liebel-Flarsheim Company, LLC – New Voluntary Recall – July 31, 2026 - Liebel-Flarsheim Company, LLC, is recalling one lot of Optiray® Imaging Bulk Package (IBP) 350, 500mL in vial, (Ioversol Injection 74% 350 mg iodine/ml) for intra-arterial or intra-venous use to the user level (hospitals, imaging centers, healthcare facilities and clinics, and other potential users of the product) due to the presence of particulate matter comprising polyethylene and other plastic materials, stainless steel and glass. <Read More>
New Generic/Biosimilar Approval and Launch
No new update
Clinical and Pharmacy News
Hidden Single-Source Risk Behind Generic Drug Supply – August 24, 2026 - Healthcare procurement teams have spent years building redundancy into pharmaceutical purchasing. A critical generic may have multiple approved manufacturers, multiple distributors and several products available for substitution, and on paper that looks diversified. Upstream, it can be something very different, and the deeper problem is that the usual numbers can still understate just how concentrated that dependency really is. <Read More>
Fewer Employers are Covering GLP-1 Drugs for Weight Loss. Should They? – August 24, 2026 - Two recent news items reveal countervailing trends in employer health insurance coverage for GLP-1 drugs, the highly effective and highly expensive medications for treating diabetes and obesity. The insurer Cigna reported a pullback in coverage of GLP-1 drugs for weight loss. Six percent of large employers dropped coverage in 2026, according to Bloomberg. Meanwhile, Bank of America is doubling down. It's continuing to cover GLP-1s for weight loss (in addition to covering them to treat diabetes), while also providing healthcare and lifestyle coaching for those on the drugs – at a cost of $250 million a year. That now represents 13% of the company's total healthcare spending. <Read More>
REMS Removed: Why CAR-T's Expansion into Community Oncology Could Benefit the Big Three Wholesalers – August 18, 2026 – The FDA's removal of CAR-T REMS requirements eliminates one obstacle to expanding treatment beyond traditional academic medical centers. That change could disproportionately benefit the Big Three wholesalers, which have spent billions building positions in community oncology while simultaneously investing in cell-and-gene-therapy distribution and support infrastructure. <Read More>
Panel Offers First Guidelines for Using E-Cigarettes to Help Smokers Quit – August 18, 2026 - A panel of experts has issued the first clinical guidelines for using e-cigarettes to help adults quit smoking. E-cigarettes should be offered alongside other smoking cessation strategies like nicotine replacement therapies or medications like varenicline and bupropion, a panel from the Society for Research on Nicotine and Tobacco said. Its recommendations were published recently in the Journal of the American Medical Association. <Read More>
States Should Not Wait Until 2028 to Open PBMs' Books – August 18, 2026 - Prescription drug prices do not become opaque by accident. They become opaque because the middlemen who manage drug benefits are allowed to hide many of their revenue streams from the employers, insurers, pharmacies, and patients who ultimately pay the bill. Congress has already recognized the problem. Federal pharmacy benefit manager (PBM) reporting requirements are scheduled to reshape what PBMs must disclose, but many of the most important provisions will not take effect until 2028. That delay creates a basic question for state lawmakers: why wait? <Read More>
Clinical Guidance: Malaria Diagnosis and Treatment in the U.S. – August 17, 2026 - Approximately 2,000 cases of malaria are reported annually in the United States, primarily among travelers. Malaria can be a severe, potentially fatal disease. Urgent diagnosis followed by immediate treatment is critical. Healthcare providers in the United States can use this guidance to ensure appropriate diagnosis and treatment of malaria. As of August 2026, guidance extends artemether-lumefantrine duration to 5 days (10 doses) for Plasmodium falciparum malaria, both for the treatment of uncomplicated infections and following IV artesunate for severe infections. <Read More>
Employers Tighten Benefits Cost Oversight as Medical and Pharmacy Pressures Mount – August 17, 2026 - More than a third of employers reported health plan premium increases of 10% or more at their latest renewal, and pharmacy and voluntary benefits are facing similar scrutiny, according to Gallagher. Medical cost pressure is intensifying even as employers make changes to health care plans intended to control it, according to Gallagher's U.S. Benefits Strategy & Benchmarking Survey. <Read More>
Major PBMs to Boost Prescription Drug Price Transparency Through TrumpRx – August 13, 2026 - A group of nine pharmacy benefit managers (PBMs) announced Thursday that they will work with an industry group to boost the transparency of prescription drug pricing through the TrumpRx platform. Fox Business exclusively learned that the Pharmaceutical Care Management Association (PCMA) and nine PBMs reached an agreement to showcase the cash price of prescriptions from TrumpRx within their benefit tools. The agreement aims to give patients better visibility into the cost of the medication and how they might save money on it. <Read More>
Employer Survey Signals Coming Shakeup in PBM Market Dynamics – August 13, 2026 – Employers are increasingly shifting business away from the big three pharmacy benefit managers of Express Scripts Inc., CVS Caremark and UnitedHealth Group's OptumRx, according to a survey released Wednesday. The three companies – which manage prescription drugs for health plans – are believed to control 80% of the market, and have garnered blowback from Congress and state regulators over opaque pricing practices and pressure on local pharmacies. <Read More>
From Blame to Data: How Medication Error Reporting Systems Drive Patient Safety – August 12, 2026 - A single medication error can have devastating consequences for patients, pharmacists, and institutions. Globally, medication-related errors are responsible for approximately 5% to 41% of all hospital admissions and 22% of readmissions. The annual costs associated with medication errors globally are approximately $42 billion. Error reporting and analysis can only decrease error rates if health care shifts its culture from one of punitive blame to one that treats errors as systemic data points for identification and correction. This requires a robust, nonpunitive reporting system coupled with systematic analysis to prevent future harm. <Read More>
The New Era of Pharma Distribution: Balancing Precision and Scale – July 14, 2026 - Specialty medicines comprise ~75% of ~7,000 pipeline assets, with nearly 180 advanced therapies expected by 2030, accelerating demand for scalable, operationally sustainable distribution models. Cold-chain exposure is rising, with ~50% of launches through 2027 requiring temperature control; 3PLs are expanding ambient-to-cryogenic capacity, including ultra-low and liquid-nitrogen storage. <Read More>
340B in the News
HRSA Revives the 340B Rebate Pilot: Covered Entities Should Prepare Now for 2027 – August 18, 2026 - HRSA is again moving toward a 340B rebate model, and covered entities should begin preparing for the possibility that the way they purchase certain 340B drugs will change on January 1, 2027. On July 31, 2026, the Health Resources and Services Administration (HRSA) announced a revised 340B Rebate Model Pilot Program. The proposal would allow qualifying manufacturers to provide the 340B ceiling price for certain drugs through a post-purchase rebate rather than the upfront discount that has long been the norm in the 340B Program. <Read More>
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs – July 7, 2026 – CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes $1.15 billion lower Original Medicare beneficiary drug costs and $4.55 billion reduced taxpayer spending, with OPPS budget neutrality offsetting via increased non-drug payments. <Read More>
Clinical Insights: August 27, 2026
New Drug/Vaccine Approval
Pasatru™ (garetosmab-grts) Injection – New Drug Approval – August 19, 2026 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Recognizing the significant mobility challenges faced by many people with FOP, Pasatru can be administered across a range of care settings, including home infusion where appropriate. <Read More>
Genglycos™ (pariglasgene brecaparvovec-opnr) Suspension for Intravenous Infusion - formerly DTX401 – New Drug Approval – August 19, 2026 - Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Genglycos™ (pariglasgene brecaparvovec-opnr), also known as DTX401, in adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). <Read More>
Zenbexus™ (iberdomide) Capsules – New Drug Approval – August 13, 2026 - The Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus™, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. <Read More>
Tauklarify™ (florquinitau F 18) Injection - formerly MK-6240 – New Drug Approval – August 13, 2026 - Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced U.S. Food and Drug Administration (FDA) approval of Tauklarify™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease to identify patients with tau neurofibrillary tangle (NFT) pathology. <Read More>
Tudriqev™ (vusolimogene oderparepvec-wtpg) Suspension for Intratumor Injection – New Drug Approval – August 6, 2026 - The Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev™, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. <Read More>
Orzeyful™ (oveporexton) Tablets – New Drug Approval – August 5, 2026 - Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved Orzeyful™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people's lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. <Read More>
mFLUSIVA® (influenza vaccine, mRNA) Injection - formerly mRNA-1010 – New Drug Approval – August 5, 2026 - Moderna, Inc. (NASDAQ:MRNA) announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA® – for adults 50 years of age and older. <Read More>
Gwyn Lo™ (ethinyl estradiol and norelgestromin) Transdermal System – New Drug Approval – July 28, 2026 - Viatris Inc. (Nasdaq: VTRS), a global healthcare company, announced that the U.S. Food and Drug Administration (FDA) has approved Gwyn Lo™ (norelgestromin and ethinyl estradiol transdermal system). Gwyn Lo™ is a new combined hormonal contraceptive (CHC) patch with low-dose estrogen. The patch has demonstrated contraceptive efficacy for women of childbearing potential with a body mass index (BMI) below 30 kg/m® who are appropriate candidates for CHC. The Gwyn Lo™ dosage is norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day. <Read More>
New Label Expansions
Imaavy® (nipocalimab-aahu) Injection – New Expanded Label – August 24, 2026 – Johnson & Johnson (NYSE: JNJ) announced the U.S. Food and Drug Administration (FDA) approval of Imaavy® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. <Read More>
Lerochol® (lerodalcibep-liga) Injection - New Expanded Label – August 13, 2026 – LIB Therapeutics, Inc. (LIB)… announced the U.S. Food and Drug Administration (FDA) has approved an autoinjector for Lerochol® (lerodalcibep-liga) Injection 300 mg/1.2 mL, a third-generation Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor that combines robust and sustained efficacy with once-monthly, single injection self-administration to support long-term adherence. <Read More>
Pluvicto® (lutetium lu 177 vipivotide tetraxetan) Injection - New Expanded Label – July 31, 2026 - Novartis announced the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor (ARPI) for patients with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naive/sensitive (mAPMN/S) prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer (mHSPC). <Read More>
New Drug Shortage
August 25, 2026
Liraglutide Injection (Discontinuation)
Mesalamine Capsule, Extended Release (Discontinuation)
August 24, 2026
Disopyramide Phosphate Capsule, Extended Release (Discontinuation)
August 14, 2026
Fulvestrant Injection (Discontinuation)
August 13, 2026
Diclofenac Sodium Tablet, Delayed Release (Discontinuation)
Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution (Discontinuation)
August 10, 2026
Glyburide Tablet (Discontinuation)
Updated Drug Shortage
August 25, 2026
Dexamethasone Sodium Phosphate Injection (Currently in Shortage)
Liraglutide Injection (Currently in Shortage)
Rifampin Injection (Currently in Shortage)
August 24, 2026
Atropine Sulfate Injection (Currently in Shortage)
Bupivacaine Hydrochloride Injection (Currently in Shortage)
Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection (Currently in Shortage)
Desmopressin Acetate Spray (Currently in Shortage)
Dextrose Monohydrate 50% Injection (Currently in Shortage)
Dobutamine Hydrochloride Injection (Currently in Shortage)
Dopamine Hydrochloride Injection (Currently in Shortage)
Epinephrine Bitartrate, Lidocaine Hydrochloride Injection (Currently in Shortage)
Lidocaine Hydrochloride Injection (Currently in Shortage)
Methylprednisolone Acetate Injection (Currently in Shortage)
Penicillin G Benzathine Injection (Currently in Shortage)
August 21, 2026
Bumetanide Injection (Currently in Shortage)
August 20, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
August 18, 2026
Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (Currently in Shortage)
Clindamycin Phosphate Injection (Currently in Shortage)
Furosemide Injection (Currently in Shortage)
Ketorolac Tromethamine Injection (Currently in Shortage)
Metronidazole Injection (Currently in Shortage)
Rifampin Capsule (Currently in Shortage)
New Drug Recall and Safety Alerts
Thyroid Tablets, USP 30 mg by Vitruvias Therapeutics, Inc – New Voluntary Recall – August 21, 2026 - Vitruvias Therapeutics Inc. is voluntarily recalling one lot (Lot. No. 504950) of Thyroid Tablets, USP 30 mg to the consumer level. The product is being recalled because testing confirmed the potential for the product to be superpotent. <Read More>
Glutathione 200 mg/mL Multi-Dose Vials by Optimal Balance Pharmacy – New Voluntary Recall – August 19, 2026 - Optimal Balance Pharmacy is voluntarily recalling one lot of Compounded Glutathione 200 MG/ML 30 ML Multi-Dose Vials to the patient level. The product is being recalled because pharmacy testing identified elevated bacterial endotoxin levels. <Read More>
Excel® Lactated Ringers Injection, 1000mL by B. Braun Medical Inc. – New Voluntary Recall – August 19, 2026 - B. Braun Medical Inc (B. Braun), is voluntarily recalling one lot of Excel® Lactated Ringers Injection, 1000mL to the hospital/healthcare facility level, due to the presence of particulate matter in solution identified primarily as cellulose cotton fibers, with individual particles also identified as cellulose wood fiber and polystyrene. <Read More>
Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials by Fresenius Kabi – New Voluntary Recall – August 10, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. <Read More>
Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe by Fresenius Kabi – New Voluntary Recall – August 4, 2026 - Fresenius Kabi, an operating company of the Fresenius Group, is voluntarily recalling one lot of Morphine Sulfate Injection USP, Simplist® – 2 mg/1 mL due to a label mix-up. The MicroVault labeled as morphine 2 mg/1 mL, may contain a Prefilled Syringe of Dilaudid® – 0.5 mg/0.5 mL. This recall is being conducted to the user level. <Read More>
Optiray® Imaging Bulk Package - 350, 500mL, Vial by Liebel-Flarsheim Company, LLC – New Voluntary Recall – July 31, 2026 - Liebel-Flarsheim Company, LLC, is recalling one lot of Optiray® Imaging Bulk Package (IBP) 350, 500mL in vial, (Ioversol Injection 74% 350 mg iodine/ml) for intra-arterial or intra-venous use to the user level (hospitals, imaging centers, healthcare facilities and clinics, and other potential users of the product) due to the presence of particulate matter comprising polyethylene and other plastic materials, stainless steel and glass. <Read More>
New Generic/Biosimilar Approval and Launch
No new update
Clinical and Pharmacy News
Hidden Single-Source Risk Behind Generic Drug Supply – August 24, 2026 - Healthcare procurement teams have spent years building redundancy into pharmaceutical purchasing. A critical generic may have multiple approved manufacturers, multiple distributors and several products available for substitution, and on paper that looks diversified. Upstream, it can be something very different, and the deeper problem is that the usual numbers can still understate just how concentrated that dependency really is. <Read More>
Fewer Employers are Covering GLP-1 Drugs for Weight Loss. Should They? – August 24, 2026 - Two recent news items reveal countervailing trends in employer health insurance coverage for GLP-1 drugs, the highly effective and highly expensive medications for treating diabetes and obesity. The insurer Cigna reported a pullback in coverage of GLP-1 drugs for weight loss. Six percent of large employers dropped coverage in 2026, according to Bloomberg. Meanwhile, Bank of America is doubling down. It's continuing to cover GLP-1s for weight loss (in addition to covering them to treat diabetes), while also providing healthcare and lifestyle coaching for those on the drugs – at a cost of $250 million a year. That now represents 13% of the company's total healthcare spending. <Read More>
REMS Removed: Why CAR-T's Expansion into Community Oncology Could Benefit the Big Three Wholesalers – August 18, 2026 – The FDA's removal of CAR-T REMS requirements eliminates one obstacle to expanding treatment beyond traditional academic medical centers. That change could disproportionately benefit the Big Three wholesalers, which have spent billions building positions in community oncology while simultaneously investing in cell-and-gene-therapy distribution and support infrastructure. <Read More>
Panel Offers First Guidelines for Using E-Cigarettes to Help Smokers Quit – August 18, 2026 - A panel of experts has issued the first clinical guidelines for using e-cigarettes to help adults quit smoking. E-cigarettes should be offered alongside other smoking cessation strategies like nicotine replacement therapies or medications like varenicline and bupropion, a panel from the Society for Research on Nicotine and Tobacco said. Its recommendations were published recently in the Journal of the American Medical Association. <Read More>
States Should Not Wait Until 2028 to Open PBMs' Books – August 18, 2026 - Prescription drug prices do not become opaque by accident. They become opaque because the middlemen who manage drug benefits are allowed to hide many of their revenue streams from the employers, insurers, pharmacies, and patients who ultimately pay the bill. Congress has already recognized the problem. Federal pharmacy benefit manager (PBM) reporting requirements are scheduled to reshape what PBMs must disclose, but many of the most important provisions will not take effect until 2028. That delay creates a basic question for state lawmakers: why wait? <Read More>
Clinical Guidance: Malaria Diagnosis and Treatment in the U.S. – August 17, 2026 - Approximately 2,000 cases of malaria are reported annually in the United States, primarily among travelers. Malaria can be a severe, potentially fatal disease. Urgent diagnosis followed by immediate treatment is critical. Healthcare providers in the United States can use this guidance to ensure appropriate diagnosis and treatment of malaria. As of August 2026, guidance extends artemether-lumefantrine duration to 5 days (10 doses) for Plasmodium falciparum malaria, both for the treatment of uncomplicated infections and following IV artesunate for severe infections. <Read More>
Employers Tighten Benefits Cost Oversight as Medical and Pharmacy Pressures Mount – August 17, 2026 - More than a third of employers reported health plan premium increases of 10% or more at their latest renewal, and pharmacy and voluntary benefits are facing similar scrutiny, according to Gallagher. Medical cost pressure is intensifying even as employers make changes to health care plans intended to control it, according to Gallagher's U.S. Benefits Strategy & Benchmarking Survey. <Read More>
Major PBMs to Boost Prescription Drug Price Transparency Through TrumpRx – August 13, 2026 - A group of nine pharmacy benefit managers (PBMs) announced Thursday that they will work with an industry group to boost the transparency of prescription drug pricing through the TrumpRx platform. Fox Business exclusively learned that the Pharmaceutical Care Management Association (PCMA) and nine PBMs reached an agreement to showcase the cash price of prescriptions from TrumpRx within their benefit tools. The agreement aims to give patients better visibility into the cost of the medication and how they might save money on it. <Read More>
Employer Survey Signals Coming Shakeup in PBM Market Dynamics – August 13, 2026 – Employers are increasingly shifting business away from the big three pharmacy benefit managers of Express Scripts Inc., CVS Caremark and UnitedHealth Group's OptumRx, according to a survey released Wednesday. The three companies – which manage prescription drugs for health plans – are believed to control 80% of the market, and have garnered blowback from Congress and state regulators over opaque pricing practices and pressure on local pharmacies. <Read More>
From Blame to Data: How Medication Error Reporting Systems Drive Patient Safety – August 12, 2026 - A single medication error can have devastating consequences for patients, pharmacists, and institutions. Globally, medication-related errors are responsible for approximately 5% to 41% of all hospital admissions and 22% of readmissions. The annual costs associated with medication errors globally are approximately $42 billion. Error reporting and analysis can only decrease error rates if health care shifts its culture from one of punitive blame to one that treats errors as systemic data points for identification and correction. This requires a robust, nonpunitive reporting system coupled with systematic analysis to prevent future harm. <Read More>
The New Era of Pharma Distribution: Balancing Precision and Scale – July 14, 2026 - Specialty medicines comprise ~75% of ~7,000 pipeline assets, with nearly 180 advanced therapies expected by 2030, accelerating demand for scalable, operationally sustainable distribution models. Cold-chain exposure is rising, with ~50% of launches through 2027 requiring temperature control; 3PLs are expanding ambient-to-cryogenic capacity, including ultra-low and liquid-nitrogen storage. <Read More>
340B in the News
HRSA Revives the 340B Rebate Pilot: Covered Entities Should Prepare Now for 2027 – August 18, 2026 - HRSA is again moving toward a 340B rebate model, and covered entities should begin preparing for the possibility that the way they purchase certain 340B drugs will change on January 1, 2027. On July 31, 2026, the Health Resources and Services Administration (HRSA) announced a revised 340B Rebate Model Pilot Program. The proposal would allow qualifying manufacturers to provide the 340B ceiling price for certain drugs through a post-purchase rebate rather than the upfront discount that has long been the norm in the 340B Program. <Read More>
340B Drug Payment Cuts Headline CMS Proposal to Lower Medicare Costs – July 7, 2026 – CMS proposes paying 340B-acquired drugs at ASP minus 33.4% starting CY 2027, replacing ASP plus 6%, based on survey findings that acquisition costs are well below ASP. Projected 2027 impact includes $1.15 billion lower Original Medicare beneficiary drug costs and $4.55 billion reduced taxpayer spending, with OPPS budget neutrality offsetting via increased non-drug payments. <Read More>
Ready to get started?
The Pillr Health team is here to empower your 340B program, and beyond. Reach out at the link below.
Ready to get started?
The Pillr Health team is here to empower your 340B program, and beyond. Reach out at the link below.
